[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 663
1. Bortolin MT, Zanussi S, Talamini R, Simonelli C, Pratesi C, Tedeschi R, Abbruzzese L, Manuele R, Rupolo M, Tirelli U, De Paoli P: Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT). AIDS Res Hum Retroviruses; 2010 Feb;26(2):245-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT).
  • The kinetics and predictive value of HIV-1 DNA (HIV DNA) levels in relapsed or refractory HIV lymphoma patients, treated with high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT), were investigated.
  • HIV DNA was measured by real-time PCR in the peripheral blood mononuclear cells (PBMCs) of 22 patients observed for a median follow-up of 31.0 months.
  • At baseline, HIV DNA was found to be correlated with HIV-1 RNA (HIV RNA) (r = 0.56), but not with CD4(+) counts (r = -0.10).
  • HIV RNA load was under control for the entire follow-up, while HIV DNA levels were almost always detectable (baseline levels vs. 1 year from ASCT levels, p > 0.05).
  • Baseline HIV DNA levels were significantly different between alive and deceased patients (p = 0.03), and the overall survival (OS) analysis showed that for patients with higher HIV DNA levels at baseline there was a higher and nearly significant risk of death if compared to patients with lower levels (HR, 8.33, 95% CI, 0.99-70.06, p = 0.05).
  • Our study demonstrated that high HIV DNA levels at baseline could predict overall survival after ASCT in one of the largest cohorts of HIV lymphoma patients treated with salvage therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. DNA, Viral / blood. HIV-1 / isolation & purification. Lymphoma, AIDS-Related / mortality. Stem Cell Transplantation. Viral Load


2. Cluzeau T, Mounier N: [Patients and the Web]. Bull Cancer; 2010 Oct;97(10):1133-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV infection is an infection highly publicized in recent years, we take the case of Hodgkin's disease associated with HIV to compare data from the Internet and scientific articles.
  • [MeSH-major] Information Dissemination / methods. Internet / standards. Lymphoma, AIDS-Related. Medical Informatics Applications. Patient Education as Topic / standards
  • [MeSH-minor] Anti-HIV Agents / therapeutic use. Drug Therapy, Combination / methods. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Evaluating Health Information.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663740.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


3. Kim WU, Yoo SA, Min SY, Park SH, Koh HS, Song SW, Cho CS: Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes. Clin Exp Immunol; 2006 Jun;144(3):503-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inadequate apoptosis may contribute to the synovial hyperplasia associated with rheumatoid arthritis (RA).
  • The Fas-associated death domain protein (FADD)-like interleukin (IL)-1beta-converting enzyme (FLICE)-inhibitory protein (FLIP), which is an apoptotic inhibitor, has been implicated in the resistance to Fas-mediated apoptosis of synoviocytes.
  • The increase in synoviocytes apoptosis by HCQ was associated with caspase-3 activation.

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1679-88 [10587358.001]
  • [Cites] J Rheumatol. 1996 Aug;23(8):1345-52 [8856612.001]
  • [Cites] Rheumatology (Oxford). 2000 May;39(5):471-80 [10852976.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1534-40 [10903761.001]
  • [Cites] Arthritis Rheum. 2001 Jan;44(1):21-30 [11212162.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):344-52 [11167827.001]
  • [Cites] J Clin Virol. 2001 Feb;20(3):131-5 [11166661.001]
  • [Cites] Apoptosis. 2000 Feb;5(1):61-7 [11227493.001]
  • [Cites] Arthritis Rheum. 2001 Dec;44(12):2899-908 [11762951.001]
  • [Cites] Arthritis Rheum. 2002 Jun;46(6):1512-8 [12115181.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):1087-95 [12148891.001]
  • [Cites] J Rheumatol. 2002 Aug;29(8):1609-14 [12180717.001]
  • [Cites] J Rheumatol. 2004 May;31(5):875-83 [15124245.001]
  • [Cites] Arthritis Rheum. 2004 Sep;50(9):2803-10 [15457448.001]
  • [Cites] J Cell Biol. 1981 Sep;90(3):665-9 [6169733.001]
  • [Cites] Ann Rheum Dis. 1987 Jan;46(1):42-5 [3813674.001]
  • [Cites] J Exp Med. 1991 Mar 1;173(3):569-74 [1997647.001]
  • [Cites] J Cell Physiol. 1993 Feb;154(2):433-41 [8425922.001]
  • [Cites] AIDS Res Hum Retroviruses. 1993 Jan;9(1):91-8 [8427717.001]
  • [Cites] Immunology. 1993 Sep;80(1):122-6 [8244452.001]
  • [Cites] Arthritis Rheum. 1995 Apr;38(4):485-91 [7536416.001]
  • [Cites] J Clin Invest. 1995 Sep;96(3):1631-8 [7657832.001]
  • [Cites] J Clin Invest. 1996 Jul 15;98(2):271-8 [8755634.001]
  • [Cites] Arthritis Rheum. 1996 Nov;39(11):1781-90 [8912499.001]
  • [Cites] Arthritis Rheum. 1997 May;40(5):927-35 [9153556.001]
  • [Cites] Arthritis Rheum. 1997 Jun;40(6):1096-105 [9182920.001]
  • [Cites] Nature. 1997 Jul 10;388(6638):190-5 [9217161.001]
  • [Cites] Br J Rheumatol. 1997 Jul;36(7):799-805 [9255117.001]
  • [Cites] Arthritis Rheum. 1997 Sep;40(9):1636-43 [9324018.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10895-900 [9380731.001]
  • [Cites] Gene Ther. 1998 Mar;5(3):331-8 [9614552.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):4493-7 [9794373.001]
  • [Cites] Curr Opin Immunol. 1998 Oct;10(5):552-8 [9794838.001]
  • [Cites] J Clin Invest. 1999 Jan;103(1):3-4 [9884327.001]
  • [Cites] Arthritis Rheum. 2000 May;43(5):1106-14 [10817565.001]
  • [Cites] Arthritis Rheum. 1994 Oct;37(10):1415-20 [7524507.001]
  • (PMID = 16734620.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antirheumatic Agents; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / Caspase Inhibitors; 0 / Intracellular Signaling Peptides and Proteins; 4QWG6N8QKH / Hydroxychloroquine; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC1941983
  •  go-up   go-down


Advertisement
4. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin G, Butera JN: Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist; 2010;15(3):293-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
  • BACKGROUND: Plasmablastic lymphoma (PBL) is a variant of diffuse large B-cell lymphoma commonly seen in the oral cavity of HIV-infected individuals.
  • METHODS: An extensive literature search rendered 248 cases of PBL, from which 157 were HIV(+).
  • Seventy cases with HIV-associated PBL that received chemotherapy were identified.
  • In a univariate analysis, early clinical stage and a complete response to chemotherapy were associated with longer survival.
  • CONCLUSIONS: Patients with HIV-associated PBL have a poor prognosis.
  • Prognosis is strongly associated with achieving a complete clinical response to CHOP or CHOP-like chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / complications. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(3):194 [10942339.001]
  • [Cites] J Hematol Oncol. 2009;2:47 [19909553.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):423-6 [11999580.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):622-8 [12437635.001]
  • [Cites] AIDS. 2003 Jul 4;17(10):1582-4 [12824797.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1881-5 [15223650.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] Br J Dermatol. 2005 Oct;153(4):828-32 [16181470.001]
  • [Cites] Blood. 2006 May 15;107(10):3832-40 [16410446.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):167-73 [17117144.001]
  • [Cites] Haematologica. 2007 Jan;92(1):e11-2 [17405744.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1361-4 [17577503.001]
  • [Cites] Am J Hematol. 2007 Aug;82(8):761-5 [17094093.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Oral Dis. 2009 Jan;15(1):38-45 [18939960.001]
  • [Cites] Intern Med. 2009;48(7):559-62 [19336959.001]
  • [Cites] Eur J Haematol. 2009 Jun;82(6):490-2 [19220417.001]
  • [Cites] Blood. 2009 Jun 11;113(24):6069-76 [19380866.001]
  • [Cites] AIDS. 2009 Sep 24;23(15):2029-37 [19531926.001]
  • [Cites] Am J Clin Pathol. 2009 Oct;132(4):597-605 [19762538.001]
  • [Cites] Blood. 2009 Oct 22;114(17):3533-7 [19704118.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):96-102 [11755827.001]
  • (PMID = 20167839.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC3227958
  •  go-up   go-down


5. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM: AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol; 2005 Jul 1;23(19):4430-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
  • PURPOSE: To compare outcomes of patients with HIV-Burkitt's lymphoma (HIV-BL) and HIV-diffuse large-cell lymphoma (HIV-DLCL) after treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or M-BACOD (methotrexate, bleomycin, cyclophosphamide, etoposide) in pre-highly active antiretroviral therapy (HAART) versus HAART eras.
  • PATIENTS AND METHODS: Three hundred sixty-three patients with AIDS-related lymphoma diagnosed from 1982 to 2003 were reviewed retrospectively, including 262 in the pre-HAART (HIV-BL, 117; HIV-DLCL, 145) and 101 in the HAART era (HIV-BL, 18; HIV-DLCL, 83).
  • RESULTS: There were no significant differences between groups in terms of age, sex, history of injection drug use, prior AIDS, lactate dehydrogenase level, and disease stage at diagnosis.
  • Compared with HIV-BL, HIV-DLCL was associated with significantly lower CD4 counts in the pre-HAART but not the HAART era.
  • Although the overall median survival was similar for both groups in the pre-HAART era (HIV-BL, 6.4 months v HIV-DLCL, 8.3 months; P = .43), survival was significantly worse in patients with HIV-BL in the HAART era (HIV-BL, 5.7 months v HIV-DLCL, 43.2 months; P = .0003).
  • In comparison, histology of HIV-BL and no attainment of complete remission were independent poor prognostic factors in the HAART era.
  • CONCLUSION: Survival of patients with HIV-DLCL has improved in the HAART era, along with CD4 count, whereas survival of similarly treated patients with HIV-BL remained poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Bleomycin / therapeutic use. Burkitt Lymphoma / mortality. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leucovorin / therapeutic use. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality. Methotrexate / therapeutic use. Prednisone / therapeutic use. Vincristine / therapeutic use


6. Riedel DJ, Gonzalez-Cuyar LF, Zhao XF, Redfield RR, Gilliam BL: Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection. Lancet Infect Dis; 2008 Apr;8(4):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection.
  • Plasmablastic lymphoma of the oral cavity is a form of non-Hodgkin lymphoma (NHL) and was first described in 1997.
  • We describe a case of plasmablastic lymphoma in an HIV-infected patient who presented with an expanding oral lesion and symptoms of a toothache.
  • We review all cases of plasmablastic lymphoma that have been reported in the literature.
  • Plasmablastic lymphoma is strongly associated with immunodeficiency, and most particularly, with HIV infection.
  • The pathophysiological origin of plasmablastic lymphoma has not been fully characterised, but the presence of Epstein-Barr virus (EBV) has often been documented in biopsy specimens, supporting a role for EBV in the pathogenesis of this lymphoma.
  • Infectious disease clinicians should be aware of this newly described and increasingly encountered lymphoma, since it is prominently associated with immunosuppression and may be mistaken for other entities.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Mouth / pathology. Mouth Neoplasms / diagnosis
  • [MeSH-minor] Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Agents / therapeutic use. Biopsy. Diagnosis, Differential. Head / radiography. Humans. Male. Tomography, X-Ray Computed. Toothache / etiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Lancet Infect Dis. 2010 Apr;10(4):226
  • (PMID = 18353267.001).
  • [ISSN] 1473-3099
  • [Journal-full-title] The Lancet. Infectious diseases
  • [ISO-abbreviation] Lancet Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antineoplastic Agents
  •  go-up   go-down


7. Fallo A, De Matteo E, Preciado MV, Cerqueiro MC, Escoms S, Chabay P, López E: Epstein-Barr virus associated with primary CNS lymphoma and disseminated BCG infection in a child with AIDS. Int J Infect Dis; 2005 Mar;9(2):96-103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus associated with primary CNS lymphoma and disseminated BCG infection in a child with AIDS.
  • BACKGROUND: AIDS patients are at increased risk of developing concurrent infections with viral, parasitic, fungal or mycobacterial organisms.
  • They can present constitutional symptoms of fever and weight loss, either due to infections or an underlying lymphoma which may coexist.
  • CASE REPORT: A child with HIV-AIDS and mild encephalopathy is reported, who during the course of a confirmed disseminated mycobacterial disease developed neurological impairment.
  • Post-mortem examination revealed disseminated BCG infection and Epstein-Barr associated primary CNS lymphoma.
  • CONCLUSIONS: BCG vaccination among HIV-1 infected children leads to the risk of disseminated BCG infection.
  • BCG immunization programmes should be reconsidered for children at risk of HIV infection, because the risk of delayed complications is independent of the immunological status at the time of the vaccination.
  • Only isolated cases of primary CNS lymphoma occurring in HIV-infected children have been reported, and a striking association with EBV infection has been demonstrated.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. BCG Vaccine / adverse effects. Brain Neoplasms / etiology. Burkitt Lymphoma / etiology. Tuberculosis / etiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections. Child, Preschool. Fatal Outcome. Female. Humans


8. Zoufaly A, Stellbrink HJ, Heiden MA, Kollan C, Hoffmann C, van Lunzen J, Hamouda O, ClinSurv Study Group: Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis; 2009 Jul 1;200(1):79-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.
  • BACKGROUND: AIDS-related lymphoma contributes to significant morbidity and mortality among human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART).
  • We assessed the predictive role of cumulative HIV viremia and other risk factors in the development of AIDS-related non-Hodgkin lymphoma.
  • METHODS: Data from the Clinical Surveillance of HIV Disease (ClinSurv) study, an ongoing, observational, open cohort study of HIV-infected patients from different urban areas in Germany, were analyzed using a Cox proportional hazards model.
  • RESULTS: In the Cox model, which comprised 6022 patients and 27,812 patient-years of follow-up while patients were receiving HAART from 1999 through 2006, cumulative HIV viremia was found to be independently associated with the risk of lymphoma (hazard ratio, [HR], 1.67 [95% confidence interval {CI}, 1.27-2.20]) (P < .001]).
  • This association differed markedly between lymphoma subtypes.
  • Although the association was more pronounced for Burkitt-type lymphoma (HR, 3.45 [95% CI, 1.52-7.85]) (P = .003), there was no association between cumulative HIV viremia and the incidence of primary central nervous system lymphoma (HR, 1.00 [95% CI, 0.39-2.57]) (P = .997).
  • Other risk factors associated with an increased risk in a multivariable analysis included the latest CD4 T cell count as well as age per 10-year increment.
  • CONCLUSIONS: Cumulative HIV viremia is an independent and strong predictor of AIDS-related lymphoma among patients receiving HAART.
  • The influence of cumulative HIV viremia may differ between lymphoma subtypes.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. HIV Infections / complications. Lymphoma, AIDS-Related / epidemiology. Viremia / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Infect Dis. 2009 Jul 1;200(1):8-10 [19476436.001]
  • (PMID = 19476437.001).
  • [ISSN] 0022-1899
  • [Journal-full-title] The Journal of infectious diseases
  • [ISO-abbreviation] J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Investigator] Kuehne A; Arastéh K; Kowol S; Bergmann F; Warnke M; Brockmeyer N; Mühlbächer N; Rockstroh J; Wasmuth J; Oette M; Blondin C; Esser S; Schenk-Westkamp P; Plettenberg A; Lorenzen T; Walther I; Adam A; Weitner L; Schewe K; Goey H; Fenske S; Buhk T; Gellerman H; Wassmuss K; Stoll M; Gerschmann S; Horst H; Fätkenheuer G; Kümmerle T; Gillor D; Bogner J; Sonntag B; Salzberger B; Fritzsche C
  •  go-up   go-down


9. Svec MA, Ward MH, Dosemeci M, Checkoway H, De Roos AJ: Risk of lymphatic or haematopoietic cancer mortality with occupational exposure to animals or the public. Occup Environ Med; 2005 Oct;62(10):726-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To conduct a population based, case-control study of death certificate data from 1984 to 1998 in 24 US states in order to evaluate the risk of mortality from LH neoplasms associated with occupational exposure to animals or the public.
  • METHODS: Cases were selected as those with an underlying cause of death of non-Hodgkin's lymphoma (NHL, n = 72,589), Hodgkin's disease (HD, n = 5479), multiple myeloma (n = 35,857), or leukaemia (n = 68,598); 912 615 controls were randomly selected from all remaining deaths, frequency matched on age, sex, race, and geographic region.
  • RESULTS: Occupational exposure to animals was associated with modest increased risks of mortality from all four LH cancers; these associations varied by region.
  • Occupational exposure to the public was associated with only negligible increased risk with LH cancer outcomes.
  • Occupations involving animal exposure were predominantly agricultural, and the risks associated with employment in the livestock industry exceeded the corresponding risks associated with the crop industry for all outcomes except HD.
  • CONCLUSIONS: Increased risks of NHL, HD, multiple myeloma, and leukaemia were associated with occupations that involved animal exposure.
  • Regional differences in risk imply that the risks may be associated with exposure to specific livestock or farming practices.
  • However, these associations may be confounded by other farming related exposures, such as pesticides.
  • [MeSH-minor] Animals. Case-Control Studies. Death Certificates. Disease Transmission, Infectious. Humans. Leukemia / etiology. Leukemia / microbiology. Lymphoma / etiology. Lymphoma / microbiology. Registries. Retrospective Studies. Risk Factors. United States / epidemiology. Zoonoses

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Infectious Diseases.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Work Environ Health. 1999 Feb;25(1):5-17 [10204665.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):60-9 [10361588.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):155-8 [10361601.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):159-65 [10361602.001]
  • [Cites] Am J Ind Med. 1999 Jul;36(1):186-92 [10361605.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Cancer Invest. 2000;18(4):366-80 [10808373.001]
  • [Cites] Cancer Invest. 2000;18(5):467-79 [10834031.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):78-87 [11138825.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):371-6 [11317081.001]
  • [Cites] Am J Ind Med. 2001 Jul;40(1):3-14 [11439392.001]
  • [Cites] Pathol Oncol Res. 2001;7(2):135-9 [11458277.001]
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):509-17 [11519759.001]
  • [Cites] Cancer Causes Control. 2001 Sep;12(7):635-43 [11552711.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):657-9 [11956646.001]
  • [Cites] J Occup Environ Med. 2002 May;44(5):469-74 [12024692.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):78-9 [12110734.001]
  • [Cites] Cancer Causes Control. 2002 Aug;13(6):563-71 [12195646.001]
  • [Cites] Am J Ind Med. 2002 Aug;Suppl 2:54-61 [12210683.001]
  • [Cites] Am J Ind Med. 2002 Nov;42(5):410-20 [12382254.001]
  • [Cites] J Occup Environ Med. 2003 Aug;45(8):857-68 [12915787.001]
  • [Cites] Eur J Cancer Prev. 2003 Dec;12(6):517-26 [14639130.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):425-30 [15006919.001]
  • [Cites] Epidemiology. 2004 May;15(3):352-6 [15097020.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):713-24 [15158093.001]
  • [Cites] Scand J Work Environ Health. 2004 Jun;30(3):215-22 [15250650.001]
  • [Cites] Public Health Rep. 1970 Sep;85(9):815-27 [4989476.001]
  • [Cites] Am J Epidemiol. 1971 Oct;94(4):507-10 [5165015.001]
  • [Cites] J Natl Cancer Inst. 1974 Jul;53(1):45-9 [4858064.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1489-91 [857036.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):595-604 [863541.001]
  • [Cites] Ann Intern Med. 1978 Oct;89(4):550-6 [697236.001]
  • [Cites] Am J Epidemiol. 1980 Jul;112(1):80-92 [6930819.001]
  • [Cites] N Engl J Med. 1981 Jan 15;304(3):135-40 [6255329.001]
  • [Cites] Am J Epidemiol. 1982 May;115(5):720-8 [7081203.001]
  • [Cites] Int J Epidemiol. 1982 Dec;11(4):391-7 [7152791.001]
  • [Cites] Br Med J (Clin Res Ed). 1983 Oct 8;287(6398):1017-9 [6412930.001]
  • [Cites] J Natl Cancer Inst. 1984 Feb;72(2):251-5 [6582313.001]
  • [Cites] Am J Ind Med. 1984;6(2):97-102 [6465143.001]
  • [Cites] Am J Ind Med. 1984;6(3):185-205 [6475965.001]
  • [Cites] Am J Epidemiol. 1985 May;121(5):675-83 [4014159.001]
  • [Cites] Br J Ind Med. 1986 Feb;43(2):75-83 [3753879.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):402-9 [3740040.001]
  • [Cites] Br J Cancer. 1986 Sep;54(3):493-500 [3756085.001]
  • [Cites] Int J Cancer. 1987 Feb 15;39(2):155-61 [3804490.001]
  • [Cites] Am J Vet Res. 1987 Feb;48(2):235-8 [3030166.001]
  • [Cites] Am J Epidemiol. 1987 Dec;126(6):1051-62 [3687917.001]
  • [Cites] Br J Ind Med. 1988 Jan;45(1):25-8 [3342184.001]
  • [Cites] Am J Ind Med. 1988;13(3):317-30 [3354583.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2919-22 [2834051.001]
  • [Cites] J Occup Med. 1989 Mar;31(3):270-2 [2918412.001]
  • [Cites] Int J Cancer. 1989 Apr 15;43(4):554-9 [2703267.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3605-9 [2340508.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]
  • [Cites] Am J Epidemiol. 1991 Jul 1;134(1):22-8 [1853857.001]
  • [Cites] Br J Ind Med. 1992 Feb;49(2):95-103 [1536825.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2447-55 [1568215.001]
  • [Cites] Br J Ind Med. 1993 Jan;50(1):79-84 [8431395.001]
  • [Cites] Am J Ind Med. 1993 May;23(5):729-42 [8506851.001]
  • [Cites] Soc Sci Med. 1993 Sep;37(6):771-7 [8211293.001]
  • [Cites] Am J Epidemiol. 1994 Mar 15;139(6):609-19 [8172172.001]
  • [Cites] Br J Haematol. 1994 Oct;88(2):392-4 [7803287.001]
  • [Cites] J Occup Med. 1994 Nov;36(11):1210-21 [7861265.001]
  • [Cites] Occup Environ Med. 1995 Jun;52(6):374-9 [7627313.001]
  • [Cites] Am J Ind Med. 1995 Jun;27(6):817-35 [7645576.001]
  • [Cites] Br J Haematol. 1995 Sep;91(1):154-61 [7577624.001]
  • [Cites] Lancet. 1996 Mar 2;347(9001):624-5 [8596360.001]
  • [Cites] Blood. 1996 May 15;87(10):4296-301 [8639788.001]
  • [Cites] Scand J Soc Med. 1996 Jun;24(2):114-20 [8816000.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):754-8 [8980179.001]
  • [Cites] Vet Clin North Am Food Anim Pract. 1997 Mar;13(1):177-90 [9071753.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):551-8 [9270958.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Am J Public Health. 1997 Sep;87(9):1539-43 [9314812.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Int J Epidemiol. 1997 Dec;26(6):1142-50 [9447392.001]
  • [Cites] Am J Epidemiol. 1998 Apr 15;147(8):727-38 [9554414.001]
  • [Cites] Occup Environ Med. 1998 Aug;55(8):522-7 [9849538.001]
  • (PMID = 16169919.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1740863
  •  go-up   go-down


11. Stern JI, Raizer JJ: Primary central nervous system lymphoma. Expert Rev Neurother; 2005 Nov;5(6 Suppl):S63-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma.
  • Primary central nervous system lymphoma is a stage 1E non-Hodgkin's lymphoma confined to the nervous system.
  • It is seen in immunocompetent and immunodeficient populations, the latter group associated with the Epstein-Barr virus.
  • Primary central nervous system lymphoma can affect the brain, leptomeninges, spinal cord or eyes.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Central Nervous System Neoplasms / therapy. Lymphoma / pathology. Lymphoma / therapy
  • [MeSH-minor] Diagnostic Imaging / methods. Drug Therapy / methods. Expert Testimony. Humans. Lymphoma, AIDS-Related. Prognosis. Radiotherapy / methods. Salvage Therapy / methods. Stem Cell Transplantation / methods. Steroids / therapeutic use

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Expert Rev Neurother. 2005 Nov;5(6 Suppl):1-2 [16274264.001]
  • (PMID = 16274272.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Steroids
  • [Number-of-references] 76
  •  go-up   go-down


12. Corti M, Fioti MF, Yampolsky C, Schtirbu R, Narbaitz M: Central nervous system involvement in Hodgkin's lymphoma associated with Epstein-Barr virus in a patient with AIDS: case report and review of the literature. Braz J Infect Dis; 2006 Dec;10(6):403-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system involvement in Hodgkin's lymphoma associated with Epstein-Barr virus in a patient with AIDS: case report and review of the literature.
  • Intracranial and intraspinal involvement is a rare complication of Hodgkin's disease.
  • We report a case of a patient with diagnosis of AIDS and Hodgkin's lymphoma who developed brain and spinal involvement at the time of the relapse of the neoplasm disease.
  • Mixed cellularity histology was the subtype of Hodgkin's disease in our patient; we identified the Epstein-Barr virus genome in the Reed-Sternberg cells by immunohistochemistry and in situ hybridization.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Central Nervous System Neoplasms / complications. Epstein-Barr Virus Infections / complications. Hodgkin Disease / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17420914.001).
  • [ISSN] 1413-8670
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 17
  •  go-up   go-down


13. Pivnik AV, Korovushkin VG, Parkhomenko VN, Tonkoglaz VN, Pavlova LE, Litivinova NG, Peregudova AB, Degterev DA, Gruzdev BM: [Differential diagnosis of lymphadenopathy in HIV/AIDS]. Ter Arkh; 2006;78(4):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis of lymphadenopathy in HIV/AIDS].
  • AIM: To determine the role of histological diagnosis of lymphadenopathy (LAP) associated with clinico-laboratory picture in patients with HIV infection/AIDS.
  • MATERIAL AND METHODS: Target biopsy of the peripheral lymph node was made in 80 HIV-infected patients from 2002 to 2005.
  • Tuberculosis was diagnosed in 33 (41%) patients, lymphomas--in 23(29%), lymphogranulomatosis--in 5 (6%), reactive lymphadenopathy--in 15 (19%), germinogenic tumors--in 3 (4%), sarcoidosis--in 1 (1%).
  • CONCLUSION: Biopsy of peripheral lymph nodes is an early, safe, reliable and cost-effective method of LAP diagnosis in patients with AIDS.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, AIDS-Related / diagnosis
  • [MeSH-minor] Adolescent. Adult. Biopsy. CD4 Lymphocyte Count. DNA, Viral / analysis. Diagnosis, Differential. HIV / genetics. HIV / immunology. HIV Antibodies / analysis. Humans. Middle Aged. Polymerase Chain Reaction. Retrospective Studies. Viral Load

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16821418.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / HIV Antibodies
  •  go-up   go-down


14. Baydoun HH, Bellon M, Nicot C: HTLV-1 Yin and Yang: Rex and p30 master regulators of viral mRNA trafficking. AIDS Rev; 2008 Oct-Dec;10(4):195-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human retroviruses are associated with a variety of malignancies including Kaposi's sarcoma and Epstein-Barr virus-associated lymphoma in HIV infection, T-cell leukemia/lymphoma and a neurologic disorder in human T-cell lymphotropic virus type 1 (HTLV-1) infection.
  • Both HIV and human T-cell lymphotropic virus type 1 have evolved a complex genetic organization for optimal use of their limited genome and production of all necessary structural and regulatory proteins.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1991 Feb 22;64(4):727-37 [1671761.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 28;175(1):98-103 [1998523.001]
  • [Cites] Cell. 1991 Apr 19;65(2):241-8 [2015625.001]
  • [Cites] Cell. 1991 Apr 19;65(2):281-91 [2015626.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5704-8 [1905815.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7145-9 [1871127.001]
  • [Cites] Nature. 1991 Nov 7;354(6348):80-2 [1944575.001]
  • [Cites] J Virol. 1992 Mar;66(3):1737-45 [1310774.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3005-9 [1348363.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8813-7 [1528897.001]
  • [Cites] J Biol Chem. 1992 Oct 25;267(30):21977-81 [1400509.001]
  • [Cites] J Virol. 1992 Dec;66(12):7572-5 [1433531.001]
  • [Cites] J Virol. 1993 Mar;67(3):1590-9 [8382312.001]
  • [Cites] J Virol. 1993 May;67(5):2496-502 [8474155.001]
  • [Cites] J Biol Chem. 1993 Jul 5;268(19):13930-4 [8314759.001]
  • [Cites] J Virol. 1993 Dec;67(12):7307-16 [8230454.001]
  • [Cites] Mol Biol Cell. 1993 Dec;4(12):1239-50 [8167407.001]
  • [Cites] Virology. 1994 Oct;204(1):144-52 [8091649.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Sep 30;203(3):1765-72 [7945327.001]
  • [Cites] J Virol. 1995 May;69(5):3125-33 [7707541.001]
  • [Cites] Cell. 1995 Aug 11;82(3):463-73 [7634336.001]
  • [Cites] J Cell Sci. 1995 Aug;108 ( Pt 8):2811-23 [7593322.001]
  • [Cites] Immunology. 1995 Dec;86(4):551-5 [8567020.001]
  • [Cites] Virology. 1996 Apr 15;218(2):316-25 [8610458.001]
  • [Cites] Virology. 1996 Jun 15;220(2):502-7 [8661402.001]
  • [Cites] Mol Cell Biol. 1996 Aug;16(8):4207-14 [8754820.001]
  • [Cites] J Virol. 1996 Sep;70(9):6442-5 [8709278.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):5147-55 [8756672.001]
  • [Cites] Leukemia. 1997 Jun;11(6):866-70 [9177442.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5156-64 [9271393.001]
  • [Cites] Science. 1997 Oct 3;278(5335):141-4 [9311922.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1041-50 [9323132.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1051-60 [9323133.001]
  • [Cites] Virology. 1997 Oct 13;237(1):123-8 [9344914.001]
  • [Cites] J Virol. 1998 May;72(5):4458-62 [9557741.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4701-7 [9616168.001]
  • [Cites] J Virol. 1998 Aug;72(8):6602-7 [9658105.001]
  • [Cites] Mol Cell Biol. 1998 Sep;18(9):5052-61 [9710589.001]
  • [Cites] J Virol. 1998 Nov;72(11):8659-68 [9765406.001]
  • [Cites] J Virol. 1999 May;73(5):3709-17 [10196263.001]
  • [Cites] J Virol. 1999 Aug;73(8):6436-43 [10400737.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] J Gen Virol. 2004 Dec;85(Pt 12):3765-75 [15557250.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:431-45 [15574380.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):16990-5 [15563596.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):52978-83 [15466468.001]
  • [Cites] Am J Hematol. 2005 Mar;78(3):232-9 [15726602.001]
  • [Cites] Plant Cell. 2005 Mar;17(3):927-43 [15746075.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:905-15 [15761473.001]
  • [Cites] Retrovirology. 2004;1:39 [15560845.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5938-51 [16155601.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5986-95 [16155605.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6026-34 [16155609.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6035-46 [16155610.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1553-9 [16236609.001]
  • [Cites] Arch Virol. 2006 Mar;151(3):509-24 [16195786.001]
  • [Cites] J Virol. 2006 Apr;80(7):3469-76 [16537614.001]
  • [Cites] J Virol. 2006 Jul;80(14):7052-9 [16809310.001]
  • [Cites] J Virol. 2006 Oct;80(20):10036-44 [17005681.001]
  • [Cites] J Biol Chem. 2006 Dec 1;281(48):37150-8 [17008317.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]
  • [Cites] Mol Cell Biol. 1999 Dec;19(12):8136-45 [10567539.001]
  • [Cites] Virology. 2000 Jan 5;266(1):1-7 [10612654.001]
  • [Cites] J Virol. 2000 Feb;74(3):1094-100 [10627519.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):567-72 [10662802.001]
  • [Cites] Virology. 2000 Aug 15;274(1):86-93 [10936091.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1757-64 [11080823.001]
  • [Cites] J Gen Virol. 2001 Apr;82(Pt 4):831-5 [11257188.001]
  • [Cites] Biochem J. 2001 Jun 1;356(Pt 2):297-310 [11368755.001]
  • [Cites] EMBO Rep. 2001 Oct;2(10):926-32 [11571268.001]
  • [Cites] J Virol. 2001 Dec;75(23):11515-25 [11689633.001]
  • [Cites] J Biol Chem. 2002 May 24;277(21):18744-52 [11893730.001]
  • [Cites] Arch Virol. 2002 Jun;147(6):1077-89 [12111420.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):396-406, table of contents [12208996.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5141-9 [12910251.001]
  • [Cites] Adv Cancer Res. 2003;89:69-132 [14587871.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(23):8751-61 [14612415.001]
  • [Cites] Virology. 2003 Dec 5;317(1):136-45 [14675632.001]
  • [Cites] Nat Med. 2004 Feb;10(2):197-201 [14730358.001]
  • [Cites] J Virol. 2004 Apr;78(8):3837-45 [15047799.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2527-39 [15353305.001]
  • [Cites] J Virol. 2004 Oct;78(20):11077-83 [15452228.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Nov;77(11):6815-9 [6256763.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Cell. 1988 Oct 21;55(2):197-209 [3048703.001]
  • [Cites] Nature. 1988 Oct 20;335(6192):738-40 [3262832.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(19):7124-8 [3174625.001]
  • [Cites] Nature. 1989 Oct 5;341(6241):453-6 [2677743.001]
  • [Cites] Genes Dev. 1989 Oct;3(10):1534-44 [2482226.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Jun 15;169(2):469-75 [2357216.001]
  • [Cites] Nat Rev Microbiol. 2007 Feb;5(2):119-27 [17224921.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14608-15 [17360706.001]
  • [Cites] J Virol. 2007 Jun;81(11):5908-18 [17360758.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jul;8(7):574-85 [17519961.001]
  • [Cites] J Natl Cancer Inst. 2008 Jan 16;100(2):98-108 [18182620.001]
  • [Cites] Apoptosis. 2008 Jun;13(6):733-47 [18421579.001]
  • [Cites] Genes Dev. 1990 Jun;4(6):1014-22 [2116986.001]
  • [Cites] J Virol. 1990 Dec;64(12):6010-7 [2243384.001]
  • [Cites] EMBO J. 1990 Dec;9(12):4161-6 [2249670.001]
  • (PMID = 19092975.001).
  • [ISSN] 1139-6121
  • [Journal-full-title] AIDS reviews
  • [ISO-abbreviation] AIDS Rev
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI058944-04; United States / NIAID NIH HHS / AI / R01 AI 058944; United States / NIAID NIH HHS / AI / R01 AI058944; United States / NIAID NIH HHS / AI / AI058944-04; United States / NCI NIH HHS / CA / R01 CA106258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Gene Products, rex; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Viral Core Proteins; 0 / rex Protein, Human T-lymphotropic virus 1
  • [Number-of-references] 103
  • [Other-IDs] NLM/ NIHMS93091; NLM/ PMC2666328
  •  go-up   go-down


15. Gasser O, Bihl FK, Wolbers M, Loggi E, Steffen I, Hirsch HH, Günthard HF, Walker BD, Brander C, Battegay M, Hess C, Swiss HIV Cohort Study: HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med; 2007 Mar 27;4(3):e96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts.
  • BACKGROUND: In chronic HIV infection, antiretroviral therapy-induced normalization of CD4(+) T cell counts (immune reconstitution [IR]) is associated with a decreased incidence of opportunistic diseases.
  • Deficient Epstein-Barr virus (EBV)-specific CD4(+) T cell function may explain the occurrence of EBV-associated opportunistic malignancy-such as primary central nervous system (PCNS) lymphoma-despite recovery of absolute CD4(+) T cell counts.
  • METHODS AND FINDINGS: Absolute CD4(+) T cell counts and EBV-specific CD4(+) T cell-dependent interferon-gamma production were assessed in six HIV-positive individuals prior to development of PCNS lymphoma ("cases"), and these values were compared with those in 16 HIV-infected matched participants with no sign of EBV-associated pathology ("matched controls") and 11 nonmatched HIV-negative blood donors.
  • Half of the PCNS lymphoma patients fulfilled IR criteria (defined here as CD4(+) T cell counts >or=500/microl blood).
  • EBV-specific CD4(+) T cells were assessed 0.5-4.7 y prior to diagnosis of lymphoma.
  • PCNS lymphoma patients also differed with regards to this response significantly from HIV-negative blood donors (p < 0.001, confidence interval for odds ratio [0-0.14]), but there was no evidence for a difference between HIV-negative participants and the HIV-positive matched controls (p = 0.47).
  • CONCLUSIONS: Irrespective of absolute CD4(+) T cell counts, HIV-positive patients who subsequently developed PCNS lymphoma lacked EBV-specific CD4(+) T cell function.
  • [MeSH-major] CD4-Positive T-Lymphocytes / cytology. CD4-Positive T-Lymphocytes / virology. Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / virology. HIV Infections / complications. Lymphoma / complications. Lymphoma / virology
  • [MeSH-minor] Adult. Case-Control Studies. Chronic Disease. Cytomegalovirus / metabolism. Female. Herpesvirus 4, Human / metabolism. Humans. Interferon-gamma / metabolism. Male. Middle Aged. Viral Load


16. Spina M, Tirelli U: Rituximab for HIV-associated lymphoma: weighing the benefits and risks. Curr Opin Oncol; 2005 Sep;17(5):462-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab for HIV-associated lymphoma: weighing the benefits and risks.
  • PURPOSE OF REVIEW: This review discusses the potential benefits and risks of using the anti-CD20 monoclonal antibody rituximab for the treatment of HIV-associated B-cell non-Hodgkin's lymphoma.
  • RECENT FINDINGS: Studies have consistently demonstrated that rituximab improves response and survival when combined with standard chemotherapy compared with chemotherapy alone in immunocompetent patients with intermediate-grade non-Hodgkin's lymphoma.
  • Several recently reported phase II and III trials have evaluated the use of rituximab plus chemotherapy for HIV-associated B-cell non-Hodgkin's lymphoma.
  • Phase II trials combining rituximab with either standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy or infusional chemotherapy have reported encouraging results, suggesting a similar benefit in HIV-positive individuals.
  • A phase III trial comparing CHOP with CHOP-plus rituximab (R-CHOP) demonstrated a lower risk from progression of the lymphoma, but a higher risk of early and late infectious-related death in patients with a low CD4 count (< 50/microL).
  • SUMMARY: Rituximab should be used cautiously in patients with advanced HIV infection who have a CD4 count of less than 50/microL, as it seems to increase the risk of developing fatal infectious complications.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, B-Cell / drug therapy

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093796.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 19
  •  go-up   go-down


17. Nishio M, Endo T, Fujimoto K, Sato N, Sakai T, Obara M, Kumano K, Minauchi K, Koike T: Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol; 2005 Dec;75(6):527-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia.
  • [MeSH-major] Agammaglobulinemia / blood. Anemia, Hemolytic, Autoimmune / blood. B-Lymphocytes. Epstein-Barr Virus Infections / blood. Herpesvirus 4, Human. Immunologic Memory. Lymphoma, AIDS-Related / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Autoimmune Hemolytic Anemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Haematol. 2006 Jan;76(1):91. Fujimoto, Katusya [corrected to Fujimoto, Katsuya]; Kumano, Koti [corrected to Kumano, Koki]
  • (PMID = 16313268.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulins; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Rinaldi A, Capello D, Scandurra M, Greiner TC, Chan WC, Bhagat G, Rossi D, Morra E, Paulli M, Rambaldi A, Rancoita PM, Inghirami G, Ponzoni M, Moreno SM, Piris MA, Mian M, Chigrinova E, Zucca E, Favera RD, Gaidano G, Kwee I, Bertoni F: Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. Br J Haematol; 2010 May;149(4):569-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma.
  • Post-transplant lymphoproliferative disorders (PTLD) are complications of solid organ transplantation associated with severe morbidity and mortality.
  • Diffuse large B-cell lymphoma (DLBCL) represents the most common form of monomorphic PTLD.
  • We studied 44 cases of post-transplant DLBCL (PT-DLBCL) with high-density genome wide single nucleotide polymorphism-based arrays, and compared them with 105 cases of immunocompetent DLBCL (IC-DLBCL) and 28 cases of Human Immunodeficiency Virus-associated DLBCL (HIV-DLBCL).
  • PT-DLBCL showed a genomic profile with specific features, although their genomic complexity was overall similar to that observed in IC- and HIV-DLBCL.
  • Changes in PT-DLBCL were partially different to those in HIV-DLBCL, suggesting different pathogenetic mechanisms in the two conditions linked to immunodeficiency.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / genetics. Organ Transplantation / adverse effects. Polymorphism, Single Nucleotide
  • [MeSH-minor] Comparative Genomic Hybridization. DNA, Neoplasm / genetics. Gene Expression Profiling / methods. Genetic Predisposition to Disease. Humans. Immunocompromised Host. Loss of Heterozygosity. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / immunology. Recurrence

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230398.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


19. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM: Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer; 2008 Dec 1;123(11):2658-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited.
  • Endemic Burkitt lymphoma (BL) is etiologically associated with Epstein-Barr virus and ecologically linked to Plasmodium falciparum malaria.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Hum Genet. 1997 Nov;101(1):1-5 [9385359.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1125-6 [18300307.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):319 [18380064.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1319-23 [18000823.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):936-43 [17697088.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Am J Trop Med Hyg. 2006 Aug;75(2):219-25 [16896122.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):56-61 [8220424.001]
  • [Cites] IARC Sci Publ. 1985;(60):177-86 [3905588.001]
  • [Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]
  • [Cites] IARC Sci Publ. 1984;(63):665-74 [6536627.001]
  • [Cites] J Clin Immunol. 1985 Mar;5(2):65-77 [3886684.001]
  • [Cites] Int J Cancer. 1980 Feb 15;25(2):197-203 [7390649.001]
  • [Cites] Int J Cancer. 1979 Mar 15;23(3):330-6 [437917.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Community Dent Health. 2005 Sep;22(3):146-50 [16161877.001]
  • [Cites] West Afr J Med. 2005 Apr-Jun;24(2):139-42 [16092315.001]
  • [Cites] Early Hum Dev. 2005 Jan;81(1):123-9 [15707724.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):738-46 [15581545.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Br J Cancer. 1969 Jun;23(2):235-46 [5788031.001]
  • [Cites] Br Med J. 1971 May 29;2(5760):491-2 [4325452.001]
  • [Cites] Lancet. 1974 Jul 6;2(7871):19-22 [4134408.001]
  • [Cites] Ann Intern Med. 1975 Jul;83(1):31-6 [1147436.001]
  • [Cites] Br J Cancer. 1977 May;35(5):668-73 [861150.001]
  • [Cites] Br J Cancer. 1978 Jan;37(1):109-22 [619954.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • (PMID = 18767045.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NCI NIH HHS / CP / N02CP31003; United States / NCI NIH HHS / CP / N02-CP-31003; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS54919; NLM/ PMC2574984
  •  go-up   go-down


20. Moyo TK, Richards KL, Damania B: Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma. Clin Adv Hematol Oncol; 2010 May;8(5):372-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma.

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIDOFOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2004 Jan;113(1):124-36 [14702116.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4423-7 [14581441.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Drugs. 1996 Aug;52(2):225-230; discussion 231 [8841740.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Ann Intern Med. 1997 Feb 15;126(4):257-63 [9036797.001]
  • [Cites] AIDS. 1997 Sep;11(11):1327-32 [9302441.001]
  • [Cites] Antimicrob Agents Chemother. 1997 Dec;41(12):2754-6 [9420052.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):339-44 [9525435.001]
  • [Cites] Leukemia. 2005 Mar;19(3):473-6 [15674353.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4372-80 [15994147.001]
  • [Cites] J Infect Dis. 2006 Mar 15;193(6):773-82 [16479510.001]
  • [Cites] Int J Hematol. 2006 May;83(4):328-30 [16757433.001]
  • [Cites] Ann Oncol. 2006 Dec;17(12):1849-50 [16766593.001]
  • [Cites] AIDS Patient Care STDS. 2004 Feb;18(2):67-73 [15006181.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2603-5 [10630536.001]
  • [Cites] AIDS. 2001 Jan 26;15(2):280-2 [11216942.001]
  • [Cites] AIDS. 2001 Oct 19;15(15):2061-2 [11600842.001]
  • [Cites] Hematol J. 2001;2(3):172-9 [11920242.001]
  • [Cites] Haematologica. 2002 Apr;87(4):339-43 [11940475.001]
  • [Cites] J Infect Dis. 2003 Jan 1;187(1):149-53 [12508160.001]
  • [Cites] Am J Hematol. 2003 Jul;73(3):143-8 [12827649.001]
  • [Cites] N Engl J Med. 2003 Sep 18;349(12):1107-9 [13679522.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [CommentOn] Clin Adv Hematol Oncol. 2010 May;8(5):367-74 [20551896.001]
  • (PMID = 20551897.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA096500-10; United States / NCI NIH HHS / CA / R01 CA096500; United States / NCI NIH HHS / CA / R01 CA096500-10
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  • [Number-of-references] 25
  • [Other-IDs] NLM/ NIHMS284696; NLM/ PMC3072025
  •  go-up   go-down


21. Miralles P, Berenguer J, Ribera JM, Rubio R, Mahillo B, Téllez MJ, Lacruz J, Valencia E, Santos J, Rodríguez-Arrondo F, Pintado V, Grupo de Estudio del SIDA Register of Systemic AIDS-Related Lymphomas: Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. J Acquir Immune Defic Syndr; 2007 Feb 1;44(2):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
  • OBJECTIVES: To assess complete remission (CR) and survival in patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) receiving highly active antiretroviral therapy (HAART).
  • METHODS: We analyzed the Grupo de Estudio del SIDA register of systemic ARL, which started in Jan 1994, to collect cases diagnosed at 15 institutions prospectively and with active follow-up every 6 months.
  • Histologic subtypes were diffuse large B-cell lymphoma (DLCL; n = 153 [72.9%]), Burkitt and atypical Burkitt/Burkitt-like lymphoma (BL; n = 40 [19.0%]), T-cell lymphoma (TC; n = 8 [3.8%]), and miscellaneous (n = 9 [4.3%]).
  • Factors independently associated with CR were histologic subtype and International Prognostic Index (IPI) score.
  • Factors independently associated with improved overall length of survival (OS) were CR, low IPI score, and histologic subtype.
  • The single factor independently associated with disease-free survival was Ann Arbor stage.
  • CONCLUSIONS: In patients with ARL treated with HAART, CR was associated exclusively with tumor-related factors.
  • OS was independently associated with CR, IPI score, and the histologic subtype.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Longitudinal Studies. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Remission Induction. Statistics as Topic. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17117144.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


22. Hernández-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R: Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res; 2006 Oct;37(7):899-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drugs most frequently associated with ACDR were amoxicillin clavulanate (8), amphotericin B (2) and metamizole (4).
  • AIDS patients showed a risk of 8.68 (CI 95% 2.18-33.19 p <0.001).
  • Non-Hodgkin's lymphoma patients also had an increased risk of developing an ACDR.
  • Six of the 35 identified cases were patients who had been hospitalized due to a severe drug reaction (1.3/1000 patients); one died from complications directly related to the ACDR, representing a 16.6% mortality rate among those admitted for an ACDR and 0.02% among the global mortality.
  • Pharmacovigilance with special attention to immunosuppressed SLE or AIDS patients is stressed.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / immunology. Adolescent. Adult. Aged. Aged, 80 and over. Amoxicillin / administration & dosage. Amoxicillin / adverse effects. Amphotericin B / administration & dosage. Amphotericin B / adverse effects. Clavulanic Acid / administration & dosage. Clavulanic Acid / adverse effects. Cohort Studies. Dipyrone / administration & dosage. Dipyrone / adverse effects. Female. Hospitalization. Humans. Immune Tolerance. Lupus Erythematosus, Systemic / immunology. Lymphoma, Non-Hodgkin / immunology. Male. Mexico / epidemiology. Middle Aged. Prevalence. Prospective Studies

  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. AMOXICILLIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16971233.001).
  • [ISSN] 0188-4409
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 23521W1S24 / Clavulanic Acid; 6429L0L52Y / Dipyrone; 7XU7A7DROE / Amphotericin B; 804826J2HU / Amoxicillin
  •  go-up   go-down


23. Fontas E, Kousignian I, Pradier C, Duvivier C, Poizot-Martin I, Durier C, Jarrousse B, Weiss L, Levy Y, Costagliola D, FHDH ANRS CO4 ANRS CO141: Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4. J Acquir Immune Defic Syndr; 2009 Feb 1;50(2):206-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukine-2 therapy does not increase the risk of Hodgkin or non-Hodgkin lymphoma in HIV-infected patients: results from FHDH ANRS CO4.
  • BACKGROUND: Concerns have been raised about a possible excess risk of lymphomas in HIV-infected patients exposed to interleukin 2 (IL-2) therapy.
  • Here we compared the risks of non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) in IL-2-treated and IL-2-untreated HIV-infected patients.
  • METHODS: Patients monitored through the French Hospital Database on HIV between May 1, 1995, and December 31, 2005, were enrolled in this study.
  • Lymphomas that occurred between the day after study entry and the end of follow-up were eligible for analysis.
  • After adjustment for sex and time-updated age, period, the CD4 cell counts, the plasma HIV RNA levels, and AIDS status, the relative rates of NHL and HL associated with IL-2 therapy were 0.64 (95% confidence interval, 0.25 to 1.65) and 0.33 (95% confidence interval, 0.04 to 2.86), respectively.
  • CONCLUSIONS: In this large observational study, IL-2 therapy did not increase the risk of lymphoma, either NHL or HL, in HIV-infected patients.
  • [MeSH-major] HIV Infections / drug therapy. Hodgkin Disease / epidemiology. Interleukin-1 / adverse effects. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Databases, Factual. Female. France. Hospitals. Humans. Incidence. Lymphoma, AIDS-Related / complications. Lymphoma, AIDS-Related / epidemiology. Male. Middle Aged. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131886.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1
  • [Investigator] Abgrall S; Barin F; Bentata M; Billaud E; Boué F; Burty C; Cabié A; Cotte L; De Truchis P; Duval X; Enel P; Fredouille-Heripret L; Gasnault J; Gaud C; Gilquin J; Grabar S; Katlama C; Khuong M; Lang JM; Lascaux A; Launay O; Mahamat A; Mary-Krause M; Matheron S; Meynard J; Pavie J; Pialoux G; Pilorgé F; Reynes J; Rouveix E; Simon A; Tattevin P; Tissot-Dupont H; Viard J; Viget N; Pariente-Khayat A; Salomon V; Jacquemet N; Rivet A; Abgrall S; Grabar S; Guiguet M; Lanoy E; Lièvre L; Mary-Krause M; Potard V; Selinger-Leneman H; Fichou J; Bouvet E; Crickx B; Ecobichon J; Leport C; Matheron S; Picard-Dahan C; Yeni P; Tisne-Dessus D; Salmon D; Sicard D; Auperin I; Gilquin J; Roudière L; Viard J; Boué F; Fior R; Delfraissy J; Goujard C; Jung C; Lesprit P; Desplanque N; Meynard JL; Meyohas M; Picard O; Cadranel J; Mayaud C; Pialoux G; Bricaire F; Herson S; Katlama C; Simon A; Clauvel J; Decazes JM; Gerard L; Molina JM; Diemer M; Sellier P; Berthé H; Dupont C; Chandemerle C; Mortier E; de Truchis P; Bentata M; Honoré P; Jeantils V; Tassi S; Mechali D; Taverne B; Gourdon F; Laurichesse H; Fresard A; Lucht F; Eglinger P; Faller JP; Bazin C; Verdon R; Boibieux A; Peyramond D; Livrozet JM; Touraine J; Cotte L; Trepo C; Ravaux I; Tissot-Dupont H; Delmont J; Moreau J; Gastaut J; Retornaz F; Soubeyrand J; Allegre T; Blanc P; Galinier A; Ruiz J; Lepeu G; Granet-Brunello P; Esterni J; Pelissier L; Cohen-Valensi R; Nezri M; Chadapaud S; Laffeuillade A; Reynes J; May T; Rabaud C; Billaud E; Raffi F; Pugliese P; Arvieux C; Michelet C; Borsa-Lebas F; Caron F; Fraisse P; Lang J; Rey D; Arlet-Suau E; Cuzin L; Massip P; Thiercelin Legrand M; Yazdanpanah Y; Pradinaud R; Sobesky M; Gaud C; Contant M; Lévy Y; Aboulker J; Bursachi P; Delfraissy J; Saïdi Y; Lascaux A; Saïdi S; Commoy M; Chêne G; Viard JP; Molina J; Tubiana R; Lascaux AS; Berdah M; Jung C; Molina J; Lafaurie M; Schnell-Niedbalski L; Oksenhendler E; Gérard L; Delfraissy J; Goujard C; Chaix F; Rannou MT; Tegna L; Tisne-Dessus D; Jeanblanc F; Beck-Wirth G; Benomar M; Verdon R; Bazin C; Goubin P; Girard P; Boudraa C; Sebire M; Viard J; Maignan A; Tubiana R; Katlama C; Curjol A; Fabre G; Trepo C; Brochier C; Thoirain V; Bloch M; Mortier E; Dupon M; Raymond I; Ragnaud JM; Raymond I; Sellier P; Magnier JD; Simon A; Iguerstira M; Gastaut J; Dalmas AM; Aboulker J; Guéguen S; Circosta S; Mourlhou P; Saouzanet-Harel M; Izard S; Saïdi Y
  •  go-up   go-down


24. Birmann BM, Breen EC, Stuver S, Cranston B, Martínez-Maza O, Falk KI, Okayama A, Hanchard B, Mueller N, Hisada M: Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica. Int J Cancer; 2009 Feb 1;124(3):614-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.
  • The differences include contrasting patterns of risk of adult T-cell lymphoma (ATL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), which may be due in part to differences in host immune response to infection.
  • HTLV-I infection was associated with activated T-cell immunity in Jamaicans but with diminished T-cell immunity in Japanese persons.
  • The observed population differences in background and HTLV-I-related host immunity correspond closely to the divergent natural histories of infection observed among HTLV-I carriers in Japan and Jamaica and corroborate a role for host immune status in the contrasting patterns of ATL and HAM/TSP risk.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • [Cites] J Med Virol. 2007 Jul;79(7):977-86 [17516523.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5218-22 [2367534.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1705-9 [11080814.001]
  • [Cites] J Infect Dis. 2001 Jan 15;183(2):197-205 [11120926.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1154-9 [11238501.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):433-40 [12115526.001]
  • [Cites] Cancer Causes Control. 2002 Sep;13(7):657-63 [12296513.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] Circulation. 2003 Jan 28;107(3):391-7 [12551861.001]
  • [Cites] Virology. 2003 Mar 30;308(1):1-12 [12706085.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):458-67 [12879461.001]
  • [Cites] Inflamm Res. 2003 Aug;52(8):313-21 [14504669.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1385-91 [15298962.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1605-9 [15478065.001]
  • [Cites] Int J Cancer. 1983 Feb 15;31(2):197-200 [6298126.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jan;84(2):570-4 [3025881.001]
  • [Cites] J Med Virol. 1987 Feb;21(2):109-21 [3029317.001]
  • [Cites] Int J Cancer. 1988 Dec 15;42(6):829-31 [3192326.001]
  • [Cites] Clin Exp Immunol. 1990 Aug;81(2):207-11 [2143707.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3(10):1006-9 [2398453.001]
  • [Cites] Ann Intern Med. 1990 Oct 15;113(8):619-27 [2205142.001]
  • [Cites] Am J Epidemiol. 1991 Jun 1;133(11):1114-24 [2035515.001]
  • [Cites] J Cell Biochem. 1991 Aug;46(4):302-11 [1757474.001]
  • [Cites] Eur J Cancer. 1993;29A(11):1584-9 [8217366.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1573-8 [8068947.001]
  • [Cites] J Clin Immunol. 1994 Nov;14(6):327-39 [7883860.001]
  • [Cites] Hokkaido Igaku Zasshi. 1995 Mar;70(2):315-28 [7774883.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S2-7 [8797696.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Sep;5(9):699-704 [8877061.001]
  • [Cites] Clin Microbiol Rev. 1996 Oct;9(4):532-62 [8894351.001]
  • [Cites] Am J Trop Med Hyg. 1997 Jan;56(1):71-5 [9063365.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1996;67:261-390 [9103967.001]
  • [Cites] Br J Haematol. 1998 Jan;100(1):129-34 [9450801.001]
  • [Cites] Clin Diagn Lab Immunol. 1998 Nov;5(6):755-61 [9801330.001]
  • [Cites] J Med Virol. 2006 Jun;78(6):847-52 [16628590.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):970-4 [2786510.001]
  • [Cites] Blood. 1989 Jul;74(1):1-10 [2473791.001]
  • [Cites] Jpn J Cancer Res. 1989 Jun;80(6):506-8 [2503470.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):869-74 [2159438.001]
  • [Cites] Clin Exp Immunol. 2000 Feb;119(2):259-63 [10632660.001]
  • (PMID = 18989900.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA038450-15; United States / NCI NIH HHS / CA / CA115687-01A1; United States / NCI NIH HHS / CA / R01 CA038450-15; United States / NCI NIH HHS / CA / K07 CA115687-01A1; United States / NCI NIH HHS / CA / K07 CA115687; United States / NCI NIH HHS / CA / CA115687-02; United States / NCI NIH HHS / CA / R01 CA038450-14; United States / NCI NIH HHS / CA / K07 CA115687-03; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / CA115687-03; United States / NCI NIH HHS / CA / CA115687; United States / NCI NIH HHS / CA / CA09001; United States / NCI NIH HHS / CA / CA038450-14; United States / NCI NIH HHS / CA / T32 CA009001; United States / NCI NIH HHS / CA / CA38450; United States / NCI NIH HHS / CA / K07 CA115687-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, Viral
  • [Other-IDs] NLM/ NIHMS99048; NLM/ PMC2701897
  •  go-up   go-down


25. Ezzat H, Filipenko D, Vickars L, Galbraith P, Li C, Murphy K, Montaner JS, Harris M, Hogg RS, Vercauteren S, Leger CS, Zypchen L, Leitch HA: Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV Clin Trials; 2007 May-Jun;8(3):132-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.
  • PURPOSE: Recent trials suggest serious toxicity in HIV-associated non-Hodgkin's lymphoma (NHL) with rituximab (R) and chemotherapy (CT), offsetting the benefit of rituximab.
  • METHOD: We retrospectively reviewed experience with CHOP-R vs. CT in 40 patients with HIV-associated diffuse large B-cell lymphoma (DLBCL) diagnosed between December 1992 and February 2006, all of whom were treated with curative intent.
  • RESULTS: In a univariate analysis, International Prognostic Index (IPI) score, prior AIDS, HAART, and rituximab were significant for overall survival (OS).
  • In a multivariate analysis, IPI 0-1 (p < .02), no prior AIDS (p < .0002), and receiving CHOP-R (p < .01) were significant for improved OS, and HAART use (p < .09) retained a trend for improved OS.
  • Patients without prior AIDS receiving CHOP-R had an HR of 0.5 (95% CI 0.1-1.7).
  • Rituximab-treated patients had a lower death rate from lymphoma (CHOP-R, 2 [16%] vs. CT, 15 [63%]; p < .04), and overall mortality (CHOP-R, 5 [42%] vs. CT, 21 [88%]; p < .01).
  • CONCLUSION: These retrospective data suggest that fatal toxicity of rituximab in HIV-NHL is not increased provided HAART is used, that the addition of rituximab to CT improved outcome, and that further prospective trials investigating this issue are warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / complications. HIV Infections / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality


26. Kamana NK, Wanchu A, Sachdeva RK, Kalra N, Rajawanshi A: Tuberculosis is the leading cause of lymphadenopathy in HIV-infected persons in India: results of a fine-needle aspiration analysis. Scand J Infect Dis; 2010 Dec;42(11-12):827-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculosis is the leading cause of lymphadenopathy in HIV-infected persons in India: results of a fine-needle aspiration analysis.
  • HIV infection is associated with a number of opportunistic infections and malignancies frequently involving the lymph nodes.
  • Lymphadenopathy may occur at any stage of HIV infection.
  • We aimed to determine the utility of fine-needle aspiration cytology in evaluating the causes of lymphadenopathy in HIV-infected individuals.
  • Three hundred HIV-infected individuals with lymphadenopathy were included in the study.
  • Lymphoma was noted in 7 individuals and suppurative inflammation in 5.
  • In conclusion, tuberculosis is the predominant cause of lymphadenitis in HIV-infected individuals in India, especially in those with low CD4 cell counts.
  • [MeSH-major] AIDS-Related Opportunistic Infections / epidemiology. HIV Infections / complications. Lymphatic Diseases / epidemiology. Lymphatic Diseases / etiology. Tuberculosis, Lymph Node / epidemiology


27. Deffenbacher KE, Iqbal J, Liu Z, Fu K, Chan WC: Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression. J Acquir Immune Defic Syndr; 2010 May 1;54(1):18-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent chromosomal alterations in molecularly classified AIDS-related lymphomas: an integrated analysis of DNA copy number and gene expression.
  • HIV-infected individuals have a significantly increased risk of developing an aggressive B-cell Non-Hodgkin Lymphoma relative to HIV(-) persons.
  • Due to their aggressive nature, AIDS-related lymphomas (ARL) can also be more difficult to classify.
  • Genetic abnormalities are known to play a significant role in HIV(-) lymphomagenesis.
  • Gene expression-based predictors robustly classified the B-ARL cases, distinguishing Burkitt lymphoma and diffuse large B-cell lymphoma, and identifying activated B-cell like and germinal center B-cell like molecular subtypes of diffuse large B-cell lymphoma.
  • These data demonstrate the ability to molecularly classify B-ARL lymphomas by gene expression and identified DNA copy number alterations targeted in B-ARL.
  • [MeSH-major] Chromosome Aberrations. Gene Dosage. Gene Expression. HIV Infections / complications. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / pathology
  • [MeSH-minor] Adult. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Comparative Genomic Hybridization. Diagnosis, Differential. Female. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216076.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U01/CA114778; United States / NCI NIH HHS / CA / 5U01/CA114778-02S1; United States / NCRR NIH HHS / RR / P20 RR016469; United States / NCI NIH HHS / CA / U01/CA84967
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Gotoh M, Kitahara T, Iguchi T, Izumi M, Mukai K, Ohyashiki K: [HIV-related multiple non-Hodgkin lymphomas]. Rinsho Ketsueki; 2008 Nov;49(11):1552-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HIV-related multiple non-Hodgkin lymphomas].
  • He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).
  • We diagnosed double lymphomas related to AIDS.
  • The patient received anti-retroviral therapy, and started the CHOP regimen for the double lymphomas, resulting in transient improvement.
  • Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.
  • This case suggested that cancer generation was promoted by low immunity, although it is known that ambivalent tumors such as non-Hodgkin lymphomas can occur frequently.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047787.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


29. Arav-Boger R: Treatment for Kaposi sarcoma herpesvirus: great challenges with promising accomplishments. Virus Genes; 2009 Apr;38(2):195-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi sarcoma-associated herpesvirus (KSHV) is associated with three distinct malignancies: Kaposi sarcoma (KS), primary effusion lymphoma, and multicentric Castleman disease.
  • This review describes multiple classes of pharmacological compounds that have been studied in patients with KS, including antivirals, chemotherapeutics, and novel agents related to KSHV pathogenesis.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):990-8 [15598977.001]
  • [Cites] Curr Opin Oncol. 2005 Sep;17(5):447-55 [16093794.001]
  • [Cites] Crit Rev Immunol. 2007;27(5):401-14 [18197804.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2082-6 [9151779.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1389-94 [16549833.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):133-43 [16904612.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2165-73 [17082322.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Jul 1;18(3):203-9 [9665496.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:289-307 [17089802.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] Int J STD AIDS. 1999 Jun;10 (6):369-75 [10414879.001]
  • [Cites] Science. 1993 Dec 10;262(5140):1721-4 [7903123.001]
  • [Cites] Am J Transplant. 2006 Sep;6(9):2164-8 [16780549.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):149-53 [16394845.001]
  • [Cites] N Engl J Med. 2007 Sep 27;357(13):1352-3 [17898112.001]
  • [Cites] J Clin Oncol. 1986 Apr;4(4):544-51 [3958767.001]
  • [Cites] J Biol Chem. 2007 Nov 23;282(47):34510-24 [17881360.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):642-52 [15765147.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):763-83 [12852655.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1792-801 [17568816.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1495-502 [16679162.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2593-602 [10893291.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Apr;16(4):495-504 [17371197.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 Mar;22(3):297-302 [18269597.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):417-25 [2415251.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2571-8 [17119113.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1444-9 [9552050.001]
  • [Cites] Cancer Invest. 2005;23 (8):653-9 [16377582.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):86-9 [9422510.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1712-9 [16520466.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):16-23 [9892104.001]
  • [Cites] Blood. 2005 May 15;105(10):4028-34 [15687238.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3948-54 [14581418.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):683-91 [9469358.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2510-8 [15572586.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):659-62 [17001705.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1112-21 [9508198.001]
  • [Cites] Nat Med. 2008 Oct;14(10):1118-22 [18776891.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):452-7 [17762570.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):535-6; author reply 536 [18234764.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1097-102 [10339664.001]
  • [Cites] Lancet Oncol. 2007 Feb;8(2):167-76 [17267331.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):1000-6 [16570046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7046-50 [1323124.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):982-9 [15572730.001]
  • [Cites] Leukemia. 1994;8 Suppl 3:S26-32 [7808021.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1876-83 [10561228.001]
  • [Cites] Infection. 2005 Jun;33(3):140-7 [15940415.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):168-74 [16397229.001]
  • [Cites] Expert Opin Ther Targets. 2007 May;11(5):589-99 [17465719.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):823-9 [7850796.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4650-7 [16507779.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2634-9 [16638877.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] AIDS. 1998 Nov 12;12(16):2169-76 [9833858.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Cell Cycle. 2007 Sep 15;6(18):2205-9 [17890905.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1736-42 [9586886.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):81-4 [14758138.001]
  • [Cites] J Infect Dis. 2008 Jul 1;198(1):23-30 [18491970.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] Mol Cell Biol. 1997 Jul;17(7):4159-68 [9199351.001]
  • [Cites] Biochem Pharmacol. 2004 Dec 15;68(12):2359-66 [15548382.001]
  • [Cites] Ann Intern Med. 1990 Jun 1;112(11):812-21 [1971504.001]
  • [Cites] J Virol. 2003 Mar;77(5):3301-6 [12584354.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1632-4 [14615380.001]
  • (PMID = 19139983.001).
  • [ISSN] 0920-8569
  • [Journal-full-title] Virus genes
  • [ISO-abbreviation] Virus Genes
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antiviral Agents; 0 / Immunologic Factors
  • [Number-of-references] 71
  •  go-up   go-down


30. Miyake A, Dewan MZ, Ishida T, Watanabe M, Honda M, Sata T, Yamamoto N, Umezawa K, Watanabe T, Horie R: Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect; 2008 Jun;10(7):748-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epstein-Barr virus (EBV) causes EBV-associated lymphoproliferative diseases in patients with profound immune suppression.
  • Most of these diseases are life-threatening and the prognosis of AIDS-associated lymphomas is extremely unfavorable.
  • We investigated the possibility of nuclear factor kappa B (NF-kappaB) inhibition by dehydroxymethylepoxyquinomicin (DHMEQ) for the treatment and prevention of EBV-associated lymphoproliferative diseases.
  • These results suggest that NF-kappaB is a molecular target for the treatment and prevention of EBV-associated lymphoproliferative diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538617.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / Immunologic Factors; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin
  •  go-up   go-down


31. Abali H, Abali G, Aksoy S: Which one is better: AIDS related or HIV associated? J Clin Oncol; 2007 Feb 20;25(6):e6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which one is better: AIDS related or HIV associated?
  • [MeSH-major] HIV Infections / classification. Lymphoma, AIDS-Related / classification. Terminology as Topic

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2006 Sep 1;24(25):4123-8 [16896005.001]
  • (PMID = 17308260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Letter
  • [Publication-country] United States
  •  go-up   go-down


32. Tanaka PY, Calore EE: P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract; 2007;203(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients.
  • It still needs to be clarified whether P-gp expression has a significant impact on non-Hodgkin's lymphoma treatment response, but a poor outcome has been reported in patients with positive P-gp expression.
  • AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
  • In an attempt to determine a possible relationship between MDR and poor outcome in this population, histologic samples obtained from 45 non-Hodgkin's lymphoma HIV-infected patients without previous cytotoxic therapy were submitted to immunohistochemical analysis using monoclonal antibody C494 specific for the MDR-1 isoform of P-gp.
  • In patients having achieved complete remission, the median disease-free survival (DFS) was not reached; the mean DFS was 57.2 months with DFS rates of 72.9% in three years.
  • Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Res Pract. 2007;203(10):763
  • (PMID = 17157997.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


33. Cho HH, Kim SH, Seo SH, Jung DS, Ko HC, Kim MB, Kwon KS: Oral hairy leukoplakia which occurred as a presenting sign of acute myeloid leukemia in a child. Ann Dermatol; 2010 Feb;22(1):73-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is frequently associated with AIDS, but cases in patients with other immunosuppressed states have also been reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1990 Jan;22(1):79-86 [2153716.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 Feb;5(1):5-12 [18417029.001]
  • [Cites] J Oral Pathol Med. 1989 Jan;18(1):32-4 [2545870.001]
  • [Cites] Lancet. 1986 Feb 1;1(8475):240-2 [2868257.001]
  • [Cites] J Infect Dis. 1987 Mar;155(3):475-81 [3492574.001]
  • [Cites] Lancet. 1984 Oct 13;2(8407):831-4 [6148571.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Jan;79(1):53-6 [7614162.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Nov;78(5):599-602 [7838466.001]
  • [Cites] J Oral Pathol Med. 1994 Aug;23(7):302-8 [7965885.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Oct;82(4):408-10 [8899778.001]
  • [Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 2):803-5 [9591790.001]
  • [Cites] Allergy Asthma Proc. 1999 Jan-Feb;20(1):51-5 [10076710.001]
  • [Cites] Oral Dis. 1999 Jan;5(1):76-9 [10218045.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):207-10 [10906639.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]
  • [Cites] Cutis. 2005 Aug;76(2):114-6 [16209157.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):147-50 [16321840.001]
  • [Cites] Br J Dermatol. 2006 Feb;154(2):378-9 [16433817.001]
  • [Cites] Leuk Res. 2007 Jan;31(1):67-73 [16814381.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):64-71 [17178496.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1220-1 [17875899.001]
  • [Cites] N Z Dent J. 2007 Sep;103(3):58-9 [17892032.001]
  • [Cites] MCN Am J Matern Child Nurs. 2008 Jan-Feb;33(1):50-7 [18158528.001]
  • [Cites] J Am Acad Dermatol. 2008 Apr;58(4):711-2 [18342722.001]
  • [Cites] J Oral Pathol Med. 1989 Jan;18(1):28-31 [2545869.001]
  • (PMID = 20548888.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2883404
  • [Keywords] NOTNLM ; Acute myeloid leukemia / Ebstein-Barr virus / Oral hairy leukoplakia
  •  go-up   go-down


34. Cainelli F, Temesgen Z, Vento S: HIV-associated malignancies. J Med Liban; 2006 Apr-Jun;54(2):111-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated malignancies.
  • [MeSH-major] HIV Infections / complications. Lymphoma, AIDS-Related / etiology. Sarcoma, Kaposi / etiology. Uterine Cervical Neoplasms / etiology
  • [MeSH-minor] Disease Progression. Female. HIV-1. Humans


35. Rose PP, Carroll JM, Carroll PA, DeFilippis VR, Lagunoff M, Moses AV, Roberts CT Jr, Früh K: The insulin receptor is essential for virus-induced tumorigenesis of Kaposi's sarcoma. Oncogene; 2007 Mar 29;26(14):1995-2005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi sarcoma (KS), a multifocal neoplasm of the skin that can spread to visceral organs, is the most prevalent malignant tumor in acquired immuno deficiency syndrome (AIDS) patients.
  • KS-associated herpesvirus (KSHV or HHV8) is considered the primary etiological factor of this malignancy, as well as of primary effusion lymphoma and multicentric Castleman's disease.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001305.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United States / NCHHSTP CDC HHS / PS / PS1-RR00163; United States / NCI NIH HHS / CA / R01-CA099906; United States / NHLBI NIH HHS / HL / T32 HL007781-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Naphthalenes; 0 / Organophosphonates; 0 / RNA, Small Interfering; 0 / hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester; EC 2.7.10.1 / Receptor, IGF Type 1; EC 2.7.10.1 / Receptor, Insulin; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


36. Berdis AJ: DNA polymerases as therapeutic targets. Biochemistry; 2008 Aug 12;47(32):8253-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A discussion of the biological function and mechanism of polymerases is first provided to illustrate the strategy for therapeutic intervention as well as the rational design of various nucleoside analogues that inhibit various polymerases associated with viral infections and cancer.
  • In addition, commonly used anticancer agents are described to illustrate the similarities and differences associated with various nucleoside analogues as therapeutic agents.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1992 Nov 17;31(45):10984-94 [1332748.001]
  • [Cites] J Mol Biol. 1992 Oct 20;227(4):981-4 [1433302.001]
  • [Cites] Annu Rev Biochem. 1993;62:685-713 [7688945.001]
  • [Cites] Science. 1995 Feb 17;267(5200):988-93 [7532321.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2760-4 [7535930.001]
  • [Cites] Leukemia. 1995 Oct;9 Suppl 1:S75-85 [7475321.001]
  • [Cites] Biochemistry. 1997 Nov 18;36(46):14064-70 [9369478.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702 [9671741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13471-6 [9811824.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1492-7 [9990051.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17395-8 [10364165.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):988-93 [15573120.001]
  • [Cites] Viral Immunol. 2004;17(4):535-44 [15671750.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72 [16101488.001]
  • [Cites] Biochemistry. 2005 Oct 4;44(39):13111-21 [16185079.001]
  • [Cites] Biochemistry. 2006 Jun 13;45(23):7334-40 [16752922.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52 [17023173.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):17-22 [17464242.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C12-21 [17475665.001]
  • [Cites] Drugs. 2007;67(11):1633-55 [17661532.001]
  • [Cites] Expert Opin Drug Deliv. 2007 Sep;4(5):513-31 [17880274.001]
  • [Cites] Mini Rev Med Chem. 2007 Oct;7(10):1035-9 [17979806.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):204-17 [18231906.001]
  • [Cites] Am J Hum Genet. 2008 Mar;82(3):539-66 [18319069.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Jun;52(6):2035-42 [18391035.001]
  • [Cites] Biochemistry. 2008 Aug 19;47(33):8527-37 [18652487.001]
  • [Cites] AIDS. 2000 Jan 28;14(2):F1-7 [10708276.001]
  • [Cites] Antimicrob Agents Chemother. 2000 May;44(5):1186-94 [10770750.001]
  • [Cites] J Mol Biol. 2000 Jul 7;300(2):403-18 [10873473.001]
  • [Cites] Nat Med. 2000 Dec;6(12):1375-9 [11100123.001]
  • [Cites] J Virol. 2001 May;75(10):4832-42 [11312355.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):23616-23 [11319228.001]
  • [Cites] Antivir Ther. 2001 Jun;6(2):115-26 [11491416.001]
  • [Cites] Acc Chem Res. 2001 Dec;34(12):938-45 [11747411.001]
  • [Cites] Biochemistry. 2002 Aug 27;41(34):10571-6 [12186540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14410-5 [12386343.001]
  • [Cites] DNA Repair (Amst). 2002 Feb 28;1(2):125-35 [12509259.001]
  • [Cites] J Virol. 2003 Jun;77(11):6127-37 [12743270.001]
  • [Cites] J Am Chem Soc. 2003 May 21;125(20):6016-7 [12785806.001]
  • [Cites] Curr Pharm Des. 2003;9(31):2593-613 [14529544.001]
  • [Cites] Biochemistry. 2003 Dec 23;42(50):14711-9 [14674745.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6221-4 [14722107.001]
  • [Cites] Nat Struct Mol Biol. 2004 May;11(5):469-74 [15107837.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S2-S12 [15319664.001]
  • [Cites] Curr Opin Pharmacol. 2004 Oct;4(5):453-64 [15351349.001]
  • [Cites] New Microbiol. 2004 Jul;27(3):207-14 [15460522.001]
  • [Cites] Can J Neurol Sci. 1977 May;4(2):81-8 [322829.001]
  • [Cites] J Biol Chem. 1989 May 5;264(13):7405-11 [2540193.001]
  • [Cites] J Biol Chem. 1990 Sep 25;265(27):16617-25 [1697861.001]
  • [Cites] Semin Oncol. 1990 Oct;17(5 Suppl 8):3-17 [1699280.001]
  • [Cites] Ann N Y Acad Sci. 1990;616:328-43 [2078027.001]
  • [Cites] Mol Pharmacol. 1992 Jan;41(1):64-8 [1732724.001]
  • [Cites] Am J Med. 1992 Feb 14;92(2A):3S-7S [1371038.001]
  • [Cites] J Clin Invest. 1993 May;91(5):2326-33 [8387546.001]
  • (PMID = 18642851.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118408; United States / NCI NIH HHS / CA / R01 CA118408-04; United States / NCI NIH HHS / CA / CA118408
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Nucleic Acid Synthesis Inhibitors; 0 / Reverse Transcriptase Inhibitors; EC 2.7.7.7 / DNA-Directed DNA Polymerase
  • [Number-of-references] 55
  • [Other-IDs] NLM/ NIHMS112579; NLM/ PMC2692436
  •  go-up   go-down


37. Heise W: GI-lymphomas in immunosuppressed patients (organ transplantation; HIV). Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):57-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GI-lymphomas in immunosuppressed patients (organ transplantation; HIV).
  • Gastrointestinal lymphoma plays a major role complicating different diseases presenting with immunosuppression, both primary and acquired immunodeficiency (incl.
  • HIV, transplantation, immunosuppression following chemotherapy, or inflammatory bowel disease).
  • Lymphoma in diseases with immunosuppression are clinically and pathologically heterogeneous, but share some features such as frequent involvement of extranodal sites, diffuse aggressive histology, B-cell lineage derivation, viral association with EBV and clinically aggressive courses.
  • While gastrointestinal lymphoma in congenital immunodeficiency disorders seems to be a rare event inspite of higher prevalences, in post-transplant lymphoproliferative disorders (PTLD) the gastrointestinal tract is one of the most important organs of lymphoma.
  • In HIV-associated non-Hodgkin's lymphoma, gastrointestinal lesions as the most frequent extranodal localisation occur in 30-50% of lymphoma patients, are late events of HIV infection with severe immunosuppression and are mainly diagnosed with advanced disease stages Ann Arbour III or IV.
  • With the introduction of highly active antiretroviral therapy (HAART) in the therapeutic concept in AIDS, a decrease of AIDS-related GI lymphoma was noted with improved survival rates and prognosis of lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / immunology. HIV Infections / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lymphoma / immunology. Lymphoma, AIDS-Related / immunology. Organ Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206109.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 84
  •  go-up   go-down


38. Armstrong EJ, Bhave P, Wong D, Ursell PC, Kaplan L, Yeghiazarians Y, Ai WZ: Left ventricular rupture due to HIV-associated T-cell lymphoma. Tex Heart Inst J; 2010;37(4):457-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ventricular rupture due to HIV-associated T-cell lymphoma.
  • Patients with lymphoma can develop cardiac involvement that includes malignant pericardial effusions and myocardial infiltration, but extensive myocardial invasion by tumor with resultant rupture has been reported only rarely.
  • We report a case of a patient with human immunodeficiency virus and T-cell lymphoma who presented with signs and symptoms that were suggestive of a non-ST-elevation myocardial infarction.
  • Autopsy revealed transmural infiltration of the myocardium with lymphoma and resultant rupture of the left ventricular free wall.
  • To our knowledge, this is the 1st reported case of left ventricular free-wall rupture due to transmural infiltration by human-immunodeficiency-virus-associated peripheral T-cell lymphoma.We conclude that noncoronary causes of chest pain, including direct myocardial infiltration, should be considered in immunocompromised patients with lymphoma.

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1369-77 [14523146.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):944-51 [7037154.001]
  • [Cites] Eur Heart J. 1987 May;8(5):549-52 [3609049.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Mar;19(3):365-8 [11251283.001]
  • [Cites] Ann Hematol. 2005 Aug;84(8):498-505 [15782345.001]
  • [Cites] Int J Cardiol. 2007 Apr 25;117(2):e84-5 [17331600.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):1008-11 [18464123.001]
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):75-8 [9760158.001]
  • (PMID = 20844622.001).
  • [ISSN] 1526-6702
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094143
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2929872
  • [Keywords] NOTNLM ; Acute coronary syndromes / HIV infections/complications / heart neoplasms/secondary / heart rupture / lymphatic metastasis / lymphoma, AIDS-related / lymphoma, T-cell/pathology / myocardium/pathology / neoplasm invasiveness / pericardium/pathology
  •  go-up   go-down


39. Cacoub P, Saadoun D: Hepatitis C virus infection induced vasculitis. Clin Rev Allergy Immunol; 2008 Oct;35(1-2):30-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Main factors associated with cryoglobulin production are female gender, alcohol intake above 50 g/day, extensive liver fibrosis, and steatosis.
  • Symptomatic cryoglobulins (i.e., vasculitis) are associated with older age, longer duration of infection, and main characteristics of cryoglobulin (type II, IgM kappa, high serum levels).
  • [MeSH-minor] Antiviral Agents / therapeutic use. Arthralgia / etiology. Cryoglobulinemia / etiology. Humans. Immunosuppressive Agents / therapeutic use. Kidney Diseases / etiology. Lymphoma, B-Cell / etiology. Peripheral Nervous System Diseases / etiology. Purpura / etiology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Vasculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nephrol Dial Transplant. 2003 Aug;18(8):1573-80 [12897097.001]
  • [Cites] Blood. 2003 May 15;101(10):3827-34 [12560225.001]
  • [Cites] Nephrol Dial Transplant. 1996;11 Suppl 4:25-30 [8918748.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1951-5 [14738149.001]
  • [Cites] J Infect Dis. 1990 Aug;162(2):569-70 [2115556.001]
  • [Cites] Medicine (Baltimore). 2002 Sep;81(5):398-409 [12352634.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2078-9 [14627800.001]
  • [Cites] Ann Rheum Dis. 2006 Mar;65(3):394-7 [16474032.001]
  • [Cites] J Rheumatol. 1999 Oct;26(10 ):2273-6 [10529155.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1723-32 [14724825.001]
  • [Cites] Arch Intern Med. 2005 Jan 10;165(1):101-5 [15642884.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):978-85 [12297847.001]
  • [Cites] N Engl J Med. 1977 Jun 30;296(26):1501-4 [865530.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3578-84 [11071657.001]
  • [Cites] Am J Med. 1980 Aug;69(2):287-308 [6996482.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] Arch Dermatol. 1995 Oct;131(10):1124-7 [7574827.001]
  • [Cites] Ann Intern Med. 1980 Mar;92(3):379-83 [7356231.001]
  • [Cites] J Rheumatol. 2000 Sep;27(9):2172-8 [10990230.001]
  • [Cites] Blood. 2001 Feb 15;97(4):1023-6 [11159532.001]
  • [Cites] G Chir. 2002 Aug-Sep;23 (8-9):331-3 [12564308.001]
  • [Cites] Am J Kidney Dis. 1995 Mar;25(3):361-9 [7532915.001]
  • [Cites] Eur J Clin Invest. 1997 Sep;27(9):711-8 [9352239.001]
  • [Cites] Ann Rheum Dis. 1998 Dec;57(12):728-31 [10070272.001]
  • [Cites] Clin Rheumatol. 2005 Sep;24(5):507-15 [15988558.001]
  • [Cites] J Intern Med. 1999 Feb;245(2):127-32 [10081515.001]
  • [Cites] Kidney Int. 1998 Aug;54(2):650-71 [9690235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):233-6 [8990191.001]
  • [Cites] Nephrol Dial Transplant. 2004 Dec;19(12):3054-61 [15494358.001]
  • [Cites] Br J Rheumatol. 1997 Mar;36(3):360-5 [9133969.001]
  • [Cites] Medicine (Baltimore). 2000 Jan;79(1):47-56 [10670409.001]
  • [Cites] Am J Med. 1974 Nov;57(5):775-88 [4216269.001]
  • [Cites] J Neurol. 1999 Jun;246(6):486-91 [10431776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 [14999097.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):468-73 [15659492.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12766-71 [10535997.001]
  • [Cites] Mayo Clin Proc. 1996 Jul;71(7):671-8 [8656709.001]
  • [Cites] N Engl J Med. 2001 Jul 5;345(1):41-52 [11439948.001]
  • [Cites] Gut. 2002 May;50 Suppl 3:III19-24 [11953328.001]
  • [Cites] J Rheumatol. 2004 Nov;31(11):2199-206 [15517633.001]
  • [Cites] Semin Hematol. 1991 Apr;28(2):79-94 [1876865.001]
  • [Cites] Blood. 1997 Nov 15;90(10 ):3865-73 [9354653.001]
  • [Cites] N Engl J Med. 1994 Mar 17;330(11):751-6 [8107741.001]
  • [Cites] J Hepatol. 2002 Jun;36(6):812-8 [12044533.001]
  • [Cites] Am J Med. 1966 Jun;40(6):837-56 [4956871.001]
  • [Cites] J Rheumatol. 2001 Nov;28(11):2466-73 [11708420.001]
  • [Cites] Blood. 1994 Nov 15;84(10):3336-43 [7524736.001]
  • [Cites] Science. 1989 Apr 21;244(4902):359-62 [2523562.001]
  • [Cites] Rheumatology (Oxford). 2006 Jul;45(7):842-6 [16418196.001]
  • [Cites] J Intern Med. 1995 Aug;238(2):153-60 [7629483.001]
  • [Cites] Arthritis Rheum. 1999 Oct;42(10):2204-12 [10524695.001]
  • [Cites] Ann Intern Med. 1977 Sep;87(3):287-92 [900672.001]
  • [Cites] Autoimmunity. 2003 Dec;36(8):511-8 [14984028.001]
  • [Cites] Br J Rheumatol. 1996 Oct;35(10):978-82 [8883436.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3668-78 [15529359.001]
  • [Cites] Neurology. 2003 Mar 11;60(5):808-12 [12629238.001]
  • [Cites] AIDS. 2005 Oct;19 Suppl 3:S128-34 [16251808.001]
  • [Cites] Hepatology. 2006 Jun;43(6):1337-45 [16729318.001]
  • [Cites] Semin Arthritis Rheum. 2004 Jun;33(6):355-74 [15190522.001]
  • [Cites] Muscle Nerve. 2002 Jun;25(6):909-13 [12115983.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):2032-5 [9667688.001]
  • [Cites] Nephron. 2002 Aug;91(4):627-30 [12138265.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Kidney Int. 1995 Feb;47(2):618-23 [7723249.001]
  • [Cites] Am J Med. 1987 Oct;83(4):726-30 [3674059.001]
  • [Cites] Blood. 2003 May 15;101(10):3818-26 [12506023.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3317-26 [12483738.001]
  • [Cites] Ital J Gastroenterol Hepatol. 1999 Jan-Feb;31(1):45-53 [10091102.001]
  • [Cites] Blood. 2003 Aug 1;102(3):996-9 [12714514.001]
  • [Cites] Ann Ital Med Int. 1992 Oct-Dec;7(4):209-14 [1298331.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3745-9 [11739181.001]
  • [Cites] Jpn Circ J. 1998 May;62(5):389-91 [9626910.001]
  • [Cites] QJM. 1995 Feb;88(2):115-26 [7704562.001]
  • [Cites] Acta Haematol. 1983;70(2):73-82 [6408882.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):253-61 [11438472.001]
  • [Cites] Am J Kidney Dis. 2004 Apr;43(4):617-23 [15042538.001]
  • [Cites] Hepatology. 1994 Apr;19(4):841-8 [8138255.001]
  • [Cites] Ric Clin Lab. 1979 Oct-Dec;9(4):361-8 [545644.001]
  • [Cites] Lancet. 1992 Feb 8;339(8789):321-3 [1346409.001]
  • [Cites] J Med Virol. 2002 Feb;66(2):200-3 [11782928.001]
  • (PMID = 18196478.001).
  • [ISSN] 1080-0549
  • [Journal-full-title] Clinical reviews in allergy & immunology
  • [ISO-abbreviation] Clin Rev Allergy Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 82
  •  go-up   go-down


40. Mantina H, Wiggill TM, Carmona S, Perner Y, Stevens WS: Characterization of Lymphomas in a high prevalence HIV setting. J Acquir Immune Defic Syndr; 2010 Apr;53(5):656-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of Lymphomas in a high prevalence HIV setting.
  • BACKGROUND: HIV infection has been associated with an increased risk of malignancy, both AIDS defining and non-AIDS defining.
  • METHODS: This study presents a detailed pathological description of newly diagnosed lymphomas in Johannesburg, South Africa (January 2004 and December 2006).
  • B-cell non-Hodgkin lymphoma accounted for 83%, T-cell non-Hodgkin lymphoma 3.5%, and Hodgkin lymphoma 7% of cases.
  • The overall prevalence of HIV infection was 37% (n = 709).
  • Diffuse large B-cell lymphoma (21%; n = 401) was the most common lymphoma.
  • HIV prevalence ranged from an absence in follicular or mantle cell lymphoma to a low prevalence in diseases like small lymphocytic lymphoma/chronic lymphocytic leukemia (4%) and pre-B/common ALL (5%) to a high prevalence in diffuse large B-cell lymphoma (80%), Burkitt lymphoma/leukemia (86%), and primary effusion lymphoma (100%).
  • CONCLUSIONS: This study provides a baseline for monitoring the impact of HIV and management thereof on lymphoma trends.
  • The high prevalence of HIV in certain lymphoma categories emphasizes the need for capacity to diagnose and manage dual conditions.
  • [MeSH-major] HIV / isolation & purification. HIV Infections / complications. Lymphoma, B-Cell / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Acquir Immune Defic Syndr. 2010 Jun;54(2):221
  • (PMID = 20160652.001).
  • [ISSN] 1944-7884
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / DNA, Viral
  •  go-up   go-down


41. Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, Mitrou PS, Chow KU: Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma; 2005 Feb;46(2):207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
  • Non-Hodgkin's lymphoma is an AIDS-defining disease.
  • We collected data of 214 cases of AIDS-related Lymphoma (ARL) treated at our centre from January 1984 until May 2003 and analysed them using the Kaplan-Meier-, log rank- and Cox proportional hazard-model.
  • The incidence of AIDS-related primary CNS lymphomas (PCNSL) took a comparable, yet more pronounced development.
  • Using the univariate Kaplan-Meier analysis prolonged survival was significantly associated with the achievement of a complete remission as well as with a favourable virological response to HAART.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621803.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


42. O'Hara AJ, Wang L, Dezube BJ, Harrington WJ Jr, Damania B, Dittmer DP: Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma. Blood; 2009 Jun 4;113(23):5938-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcoma.
  • We show that the absence of miRNAs likewise can be used to determine tumor origin (miR-155) and proliferation state because tumor suppressor miRNAs (miR-222/221, let-7 family) were significantly down-regulated in primary effusion lymphoma (PEL) and in Kaposi sarcoma (KS), an endothelial cell tumor.
  • PEL and KS are associated with KS-associated herpesvirus infection.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4790-9 [15256448.001]
  • [Cites] J Virol. 2007 Feb;81(4):1912-22 [17121789.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1156-61 [17487835.001]
  • [Cites] J Biol Chem. 2007 Aug 10;282(32):23716-24 [17569667.001]
  • [Cites] EMBO J. 2007 Aug 8;26(15):3699-708 [17627278.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9762-70 [17942906.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Immunity. 2007 Dec;27(6):847-59 [18055230.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2347-53 [18079361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 [18308936.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2773-80 [18413744.001]
  • [Cites] Immunity. 2008 May;28(5):630-8 [18455451.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4640-8 [18559509.001]
  • [Cites] J Virol. 2002 Aug;76(16):8383-99 [12134042.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] J Virol. 2005 Jan;79(2):1244-51 [15613351.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):982-9 [15572730.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Blood. 2006 Nov 1;108(9):3068-71 [16849646.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • (PMID = 19252139.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL083469; United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA096500; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NCI NIH HHS / CA / CA109232; United States / NCI NIH HHS / CA / CA121935; United States / NCI NIH HHS / CA / CA121947; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NIAID NIH HHS / AI / T32 AI00741; United States / NHLBI NIH HHS / HL / R01 HL083469; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / U01 CA121947; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / R01 CA096500
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2700328
  •  go-up   go-down


43. Lu TH, Chang HJ, Chen LS, Chu MH, Ou NM, Jen I: Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan. J Formos Med Assoc; 2006 Jul;105(7):604-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan.
  • To assess the pattern of change in the causes of death among HIV/AIDS patients in Taiwan after the introduction of highly active antiretroviral therapy (HAART), national HIV/AIDS registry data were linked with cause of death and health insurance claims data from 1994 to 2002 for analysis.
  • Although HIV/AIDS remained the leading underlying cause of death among HIV/AIDS patients during the study period (552/752 = 73.4%), an increased proportion of deaths was due to non-HIV/AIDS causes (other infectious diseases, cancers, liver diseases, etc.) after the introduction of HAART in 1997.
  • Most AIDS-related conditions associated with death (cryptococcosis, cachexia/wasting, dementia/encephalopathy, etc.) decreased in frequency from 1998-2000 to 2001-2002.
  • Nonetheless, some AIDS-related conditions associated with death remained stable or increased in frequency, such as candidiasis, tuberculosis, and non-Hodgkin's lymphoma.
  • More effort is required to address the mental health of HIV/AIDS patients as a part of therapy.


44. Georgountzos V, Ioannidou-Mouzaka L, Soldatos T, Apessou D, Karatasiou A, Tsouroulas M, Kontogeorgos G: Secondary involvement of breast with non-Hodgkin's lymphoma in a patient with HIV infection -- case report. Eur J Gynaecol Oncol; 2008;29(2):196-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary involvement of breast with non-Hodgkin's lymphoma in a patient with HIV infection -- case report.
  • Secondary lymphoma of the breast is a rare entity in patients with non-Hodgkin's lymphoma (NHL).
  • HIV infection is associated with an increased risk for developing NHL, however lymphomatous involvement of the breast in AIDS patients has rarely been reported.
  • We present the case of a 33-year-old HIV-infected female patient with diffuse NHL who presented with a unilateral breast mass.
  • Histologic examination of the biopsy specimen revealed a highly-malignant diffuse large B-cell lymphoma.
  • [MeSH-major] Breast Neoplasms / secondary. HIV Infections / complications. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459566.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


45. Nadella MV, Shu ST, Dirksen WP, Thudi NK, Nadella KS, Fernandez SA, Lairmore MD, Green PL, Rosol TJ: Expression of parathyroid hormone-related protein during immortalization of human peripheral blood mononuclear cells by HTLV-1: implications for transformation. Retrovirology; 2008 Jun 09;5:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of parathyroid hormone-related protein during immortalization of human peripheral blood mononuclear cells by HTLV-1: implications for transformation.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is initiated by infection with human T-lymphotropic virus type-1 (HTLV-1); however, additional host factors are also required for T-cell transformation and development of ATLL.
  • Parathyroid hormone-related protein (PTHrP) plays an important role in the pathogenesis of humoral hypercalcemia of malignancy (HHM) that occurs in the majority of ATLL patients.
  • However, PTHrP is also up-regulated in HTLV-1-carriers and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients without hypercalcemia, indicating that PTHrP is expressed before transformation of T-cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2001 Oct 5;287(4):910-3 [11573951.001]
  • [Cites] Br J Pharmacol. 2001 Nov;134(6):1113-36 [11704631.001]
  • [Cites] Blood. 2002 Jan 15;99(2):634-40 [11781248.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 Mar 1;18(4):249-51 [11860671.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):396-406, table of contents [12208996.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Dec;13(6):455-81 [12401480.001]
  • [Cites] Mol Cell. 2002 Dec;10(6):1345-53 [12504010.001]
  • [Cites] Science. 2003 Mar 14;299(5613):1713-6 [12589003.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3963-9 [12907436.001]
  • [Cites] Int J Hematol. 2003 Nov;78(4):297-303 [14686486.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1105-11 [15176993.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Cancer. 1987 Mar 15;59(6):1187-91 [2880656.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93 [3037548.001]
  • [Cites] J Clin Invest. 1987 Sep;80(3):911-6 [2887587.001]
  • [Cites] Blood. 1988 Jan;71(1):263-6 [2891388.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Nov;85(22):8526-30 [2847164.001]
  • [Cites] J Clin Invest. 1989 Mar;83(3):1057-60 [2537846.001]
  • [Cites] Nucleic Acids Res. 1989 Jun 12;17(11):4101-15 [2740212.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):413-7 [2403646.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] EMBO J. 1990 Dec;9(12):4161-6 [2249670.001]
  • [Cites] Eur J Haematol. 1992 May;48(5):278-9 [1644163.001]
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):395-400 [7812198.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2257-67 [7662973.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):702-7 [7669584.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):30857-61 [8537338.001]
  • [Cites] Physiol Rev. 1996 Jan;76(1):127-73 [8592727.001]
  • [Cites] Am J Med Sci. 1996 Dec;312(6):287-94 [8969618.001]
  • [Cites] J Virol. 1997 Feb;71(2):1181-90 [8995640.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4953-8 [9030555.001]
  • [Cites] Leukemia. 1997 Apr;11 Suppl 3:63-4 [9209299.001]
  • [Cites] J Endocrinol. 1997 Sep;154 Suppl:S23-37 [9379134.001]
  • [Cites] Annu Rev Physiol. 1998;60:431-60 [9558472.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 27;262(2):429-32 [10462492.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:431-45 [15574380.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2005;15(2):115-32 [16022632.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1175-83 [15889157.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5986-95 [16155605.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1980-8 [16263794.001]
  • [Cites] Blood. 2006 May 15;107(10):3976-82 [16424388.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):170-82 [16223565.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):133-40 [17387298.001]
  • [Cites] J Virol Methods. 2007 Jun;142(1-2):159-68 [17337070.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):135-45 [17372745.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1752-62 [17554373.001]
  • [Cites] J Emerg Med. 2000 Jan;18(1):109-19 [10645850.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):319-24 [10652420.001]
  • [Cites] Immunol Cell Biol. 2000 Aug;78(4):395-402 [10947864.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • (PMID = 18541021.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCI NIH HHS / CA / CA100730-06; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / T32 RR007073; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCI NIH HHS / CA / CA77911; United States / NCI NIH HHS / CA / P01 CA100730-06; United States / NCRR NIH HHS / RR / T32 RR07073; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokine CCL3; 0 / Gene Products, tax; 0 / PTH1R protein, human; 0 / Parathyroid Hormone-Related Protein; 0 / Receptor, Parathyroid Hormone, Type 1; 0 / tax protein, Human T-lymphotrophic virus 1
  • [Other-IDs] NLM/ PMC2435116
  •  go-up   go-down


46. Sánchez-Peña P, Romero-Guadarrama MB, Aguirre-García J: Diseases associated with HIV infection: study of biopsies and surgical resection specimens at a large general hospital in Mexico City. Ann Diagn Pathol; 2009 Jun;13(3):162-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diseases associated with HIV infection: study of biopsies and surgical resection specimens at a large general hospital in Mexico City.
  • The objective of this study was to analyze the type of diseases associated with HIV infection from a survey of the surgical pathology material accessioned at a large general hospital in Mexico City.
  • From the archives of the pathology unit of the General Hospital of Mexico (Ministry of Health), we compiled data on biopsies and surgical specimen from different organs and tissues of HIV-infected patients (HIV/AIDS) received in the period from January 2005 to July 2008.
  • The most frequent diagnoses were non-Hodgkin's large B-cell lymphoma in 11 cases (21.12%) and its morphological variants, 8 reactive lymphadenopathy cases (15.38%), 5 atypical mycobacterioses (9.61%), 2 nonspecific granulomatous lesions (3.84%), 2 Burkitt's lymphoma (3.84%), 3 Kaposi sarcoma (5.76%), 1 mixed cellularity Hodgkin's lymphoma (1.92%), 1 Kaposiform hemangioendothelioma (1.92%), and 1 with infection by cytomegalovirus + cryptosporidiosis in the duodenum (1.92%).
  • In this series, the most affected organ in patients with HIV/AIDS was the lymphatic nodes.
  • The most common neoplasm was the non-Hodgkin's lymphoma followed by Kaposi sarcoma.
  • [MeSH-major] HIV Infections / complications. Infection / epidemiology. Infection / etiology. Neoplasms / epidemiology. Neoplasms / etiology


47. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA, HIV/AIDS Cancer Match Study: AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst; 2007 Jun 20;99(12):962-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related cancer and severity of immunosuppression in persons with AIDS.
  • BACKGROUND: The incidence of Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer has been declining among persons with AIDS.
  • METHODS: Data from US AIDS registries were linked to local cancer registry data.
  • Cancer incidence per 100,000 person-years was determined for the 4-27 months from the onset of AIDS from January 1, 1990, through December 31, 1995--before highly active antiretroviral therapy (HAART) became available--and from January 1, 1996, through December 31, 2002.
  • The relationships between CD4 count at AIDS onset and cancer incidence were assessed by proportional hazards models.
  • RESULTS: Among 325,516 adults with AIDS, the incidence of Kaposi sarcoma was lower in 1996-2002 (334.6 cases per 100,000 person-years) than in 1990-1995 (1838.9 cases per 100,000 person-years), and the incidence of non-Hodgkin lymphoma followed a similar pattern (i.e., 390.1 cases per 100,000 person-years in 1996-2002 and 1066.2 cases per 100,000 person-years in 1990-1995).
  • In 1996-2002, for each decline in CD4 cell count of 50 cells per microliter of blood, increased risks were found for Kaposi sarcoma (hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.33 to 1.50), for central nervous system non-Hodgkin lymphoma subtypes (HR = 1.85, 95% CI = 1.58 to 2.16), and for non-central nervous system diffuse large B-cell lymphoma (HR = 1.12, 95% CI = 1.04 to 1.20) but not for non-central nervous system Burkitt lymphoma (HR = 0.93, 95% CI = 0.81 to 1.06).
  • After adjustment for age, race, and sex or mode of HIV exposure, the risks for Kaposi sarcoma (RR = 0.22, 95% CI = 0.20 to 0.24) and for non-Hodgkin lymphoma (RR = 0.40, 95% CI = 0.36 to 0.44) were lower in the period of 1996-2002 than in 1990-1995.
  • CONCLUSIONS: Both before and after HAART was available, CD4 count was strongly associated with risks for Kaposi sarcoma and non-Hodgkin lymphoma but not for cervical cancer and Burkitt lymphoma.
  • The decreasing incidences of most AIDS-associated cancers in persons with AIDS during the 1990s are consistent with improving CD4 counts after HAART introduction in 1996.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / immunology. Sarcoma, Kaposi / immunology
  • [MeSH-minor] Adolescent. Adult. Antiretroviral Therapy, Highly Active. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / immunology. Burkitt Lymphoma / virology. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Female. Humans. Male. Middle Aged. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / immunology. Uterine Cervical Neoplasms / virology


48. Martin P, Leonard JP, Coleman M, Furman RR: Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma; 2009 Jun;9(3):247-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis.
  • The infiltration of nonmalignant cells surrounding the Reed-Sternberg cells within the tumors of Hodgkin lymphoma (HL) might be central to the pathophysiology of the disease.
  • Severe sepsis results in a flood of cytokines that activate the immune system and is associated with generalized lymphocyte apoptosis.
  • We report on 2 patients with HIV infection and HL who achieved durable complete remissions following only one cycle of chemotherapy that was complicated by neutropenic sepsis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. HIV Infections / complications. HIV Infections / therapy. Hodgkin Disease / complications. Hodgkin Disease / therapy. Lymphoma, AIDS-Related / therapy. Remission Induction. Sepsis / complications


49. Honda M, Morikawa T, Yamaguchi Y, Tani M, Yamaguchi K, Iijima K, Akishita M, Fukayama M, Ouchi Y: [A case of a primary effusion lymphoma in the elderly]. Nihon Ronen Igakkai Zasshi; 2009;46(6):551-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of a primary effusion lymphoma in the elderly].
  • We report a 90-year-old man who was given a diagnosis of pleural effusion lymphoma (PEL) based on the detailed immunochemical and DNA analyses of the pleural effusion.
  • He was bed-ridden and on enteral nutrition due to severe Alzheimer's disease, and also had diabetes mellitus.
  • Most of the atypical cells were CD30 positive, with human herpes virus-8 (HHV-8)-associated protein.
  • PEL is a rare type of lymphoma confined to the body cavities without any prominent tumor mass, and its pathogenesis is related to HHV-8 infection.
  • PEL develops mostly in immunocompromised patients, such as those with AIDS.
  • [MeSH-major] Lymphoma, Primary Effusion / diagnosis

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139653.001).
  • [ISSN] 0300-9173
  • [Journal-full-title] Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
  • [ISO-abbreviation] Nihon Ronen Igakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Petersen PE: Oral cancer prevention and control--the approach of the World Health Organization. Oral Oncol; 2009 Apr-May;45(4-5):454-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies have shown that heavy intake of alcoholic beverages is associated with nutrient deficiency, which appears to contribute independently to oral carcinogenesis.
  • Prevention of HIV infection will also reduce the incidence of HIV/AIDS-related cancers such as Kaposi sarcoma and lymphoma.

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Oral Health.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804412.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  •  go-up   go-down


51. Subirá D, Górgolas M, Castañón S, Serrano C, Román A, Rivas F, Tomás JF: Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients. HIV Med; 2005 Jan;6(1):21-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advantages of flow cytometry immunophenotyping for the diagnosis of central nervous system non-Hodgkin's lymphoma in AIDS patients.
  • BACKGROUND: Neurological disorders are common in HIV-infected patients.
  • Central nervous system (CNS) lymphoma should always be considered because it is an important cause of morbidity and mortality.
  • OBJECTIVES: To investigate the clinical utility of flow cytometry immunophenotyping (FCI) in diagnosing or discarding leptomeningeal involvement in HIV-infected patients and to compare its sensitivity with that of conventional cytological methods.
  • METHODS: Fifty-six cerebrospinal fluid (CSF) samples from 29 HIV-infected patients were independently evaluated by flow cytometry and cytology.
  • RESULTS: FCI and cytology gave concordant results for 48 of the 56 CSF samples studied: 37 were negative for malignancy and 11 had evidence of CNS lymphoma.
  • This advantage suggests that, in case of negative flow cytometry results, disorders other than non-Hodgkin's lymphoma should be strongly considered.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Burkitt Lymphoma / cerebrospinal fluid. Burkitt Lymphoma / diagnosis. Diagnosis, Differential. Female. Flow Cytometry / methods. Humans. Immunophenotyping / methods. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670248.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


52. Mukerjee R, Deshmane SL, Fan S, Del Valle L, White MK, Khalili K, Amini S, Sawaya BE: Involvement of the p53 and p73 transcription factors in neuroAIDS. Cell Cycle; 2008 Sep 01;7(17):2682-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-associated dementia (HAD) is the most common AIDS-associated neurological disorder and is characterized by the development of synaptodendritic injury to neurons.
  • The viral protein HIV-1 Tat is among those factors and is released by HIV-1-infected cells and can be taken up by adjacent neuronal cells leading to neurotoxic effects.
  • [MeSH-major] AIDS Dementia Complex / metabolism. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Apoptosis. Apoptosis Regulatory Proteins. Brain / metabolism. Brain / pathology. Brain / virology. Cell Line, Tumor. HIV-1 / physiology. Humans. Models, Biological. Nerve Degeneration / metabolism. Nerve Degeneration / pathology. Neurons / metabolism. Neurons / pathology. Phosphorylation. Phosphoserine / metabolism. Protein Transport. Subcellular Fractions / metabolism. Up-Regulation. tat Gene Products, Human Immunodeficiency Virus / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biochem. 2007 Apr 1;100(5):1210-6 [17031851.001]
  • [Cites] Front Biosci. 2008;13:2484-94 [17981728.001]
  • [Cites] J Neurovirol. 1997 Apr;3(2):168-73 [9111179.001]
  • [Cites] FASEB J. 2004 Jul;18(10):1141-3 [15155568.001]
  • [Cites] Cell Death Differ. 2007 Mar;14(3):436-46 [16990849.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1329-39 [15359630.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):560-4 [11932750.001]
  • [Cites] J Neurochem. 1999 Aug;73(2):578-86 [10428053.001]
  • [Cites] Ann Neurol. 2001 Jun;49(6):745-52 [11409426.001]
  • [Cites] Eur J Biochem. 2001 May;268(10):2779-83 [11358492.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):799-809 [15865935.001]
  • [Cites] J Biol Chem. 2006 Feb 17;281(7):3832-40 [16330547.001]
  • [Cites] Mol Cell. 2003 Jul;12(1):167-76 [12887902.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(18):8126-38 [16135803.001]
  • [Cites] EMBO J. 2005 Feb 23;24(4):836-48 [15678106.001]
  • [Cites] Apoptosis. 2005 Dec;10(6):1419-31 [16235026.001]
  • [Cites] Curr Top Med Chem. 2004;4(9):871-82 [15134546.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):3226-36 [17312171.001]
  • [Cites] J Biomed Biotechnol. 2006;2006(3):65741 [17047310.001]
  • [Cites] World J Gastroenterol. 2006 Aug 28;12(32):5175-81 [16937528.001]
  • [Cites] J Gen Virol. 2007 Feb;88(Pt 2):631-40 [17251582.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5461-4 [7777531.001]
  • [Cites] J Leukoc Biol. 2006 Sep;80(3):659-67 [16844765.001]
  • [Cites] J Virol. 1997 Mar;71(3):2495-9 [9032389.001]
  • [Cites] Neurobiol Dis. 2007 Jun;26(3):661-70 [17451964.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):49-58 [12507556.001]
  • [Cites] Int J Cancer. 2001 Mar 15;91(6):822-7 [11275986.001]
  • [Cites] AIDS. 1997;11 Suppl A:S35-45 [9451964.001]
  • [Cites] Science. 2000 Jul 14;289(5477):304-6 [10894779.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3512-27 [9832504.001]
  • [Cites] J Neurosci Res. 2000 Mar 1;59(5):671-9 [10686595.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):49196-202 [12920125.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):279-89 [15642743.001]
  • [Cites] Trends Biochem Sci. 2003 Dec;28(12):663-70 [14659698.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):36316-23 [10961991.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):191-4 [9296498.001]
  • [Cites] J Neuroimmune Pharmacol. 2006 Jun;1(2):138-51 [18040780.001]
  • [Cites] Acta Neuropathol. 2000 Dec;100(6):647-53 [11078216.001]
  • [Cites] Cancer Lett. 2005 Oct 18;228(1-2):29-35 [15907364.001]
  • [Cites] Nat Rev Neurosci. 2007 Jan;8(1):33-44 [17180161.001]
  • [Cites] J Biol Chem. 2008 Mar 28;283(13):8555-63 [18174154.001]
  • [Cites] EMBO J. 1998 Dec 1;17(23):7056-65 [9843510.001]
  • [Cites] Neuroreport. 2000 Sep 11;11(13):2973-6 [11006977.001]
  • [Cites] J Clin Invest. 1991 Feb;87(2):503-12 [1671392.001]
  • [Cites] Mol Cell Neurosci. 2003 Sep;24(1):224-37 [14550782.001]
  • [Cites] Cell Cycle. 2003 May-Jun;2(3):233-5 [12734432.001]
  • [Cites] Ann Neurol. 2003 Nov;54(5):605-14 [14595650.001]
  • [Cites] Lab Invest. 2002 Jun;82(6):693-702 [12065679.001]
  • [Cites] J Neurosci Res. 2003 Oct 15;74(2):255-65 [14515355.001]
  • [Cites] Cell. 1997 Aug 22;90(4):809-19 [9288759.001]
  • [Cites] FEBS Lett. 2000 Jul 28;478(1-2):183-6 [10922493.001]
  • (PMID = 18719392.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS030916; United States / NINDS NIH HHS / NS / P01 NS030916-16; United States / NINDS NIH HHS / NS / R01 NS059327; United States / NINDS NIH HHS / NS / R01 NS059327-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tat Gene Products, Human Immunodeficiency Virus; 17885-08-4 / Phosphoserine
  • [Other-IDs] NLM/ NIHMS104157; NLM/ PMC2670771
  •  go-up   go-down


53. Haque M, Wang V, Davis DA, Zheng ZM, Yarchoan R: Genetic organization and hypoxic activation of the Kaposi's sarcoma-associated herpesvirus ORF34-37 gene cluster. J Virol; 2006 Jul;80(14):7037-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic organization and hypoxic activation of the Kaposi's sarcoma-associated herpesvirus ORF34-37 gene cluster.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent for Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2000 Jul;2(7):423-7 [10878807.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21048-54 [10777486.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25733-41 [10823831.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5 [10973499.001]
  • [Cites] J Biol Chem. 2001 Jan 19;276(3):2292-8 [11056166.001]
  • [Cites] J Virol. 2001 Mar;75(6):2938-45 [11222719.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Blood. 2001 May 15;97(10):3244-50 [11342455.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):24147-52 [10446188.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2001 Feb;75(4):1798-807 [11160678.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] J Virol. 2001 Feb;75(4):1864-9 [11160685.001]
  • [Cites] J Virol. 2004 Dec;78(24):13637-52 [15564474.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3299-306 [15833863.001]
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:551-78 [10611972.001]
  • [Cites] J Virol. 2000 Mar;74(6):2867-75 [10684303.001]
  • [Cites] J Gen Virol. 2000 Apr;81(Pt 4):1067-71 [10725434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9630-5 [11504942.001]
  • [Cites] Science. 2002 Feb 1;295(5556):807-8 [11823627.001]
  • [Cites] Science. 2002 Feb 1;295(5556):858-61 [11823643.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):14547-56 [11832484.001]
  • [Cites] Genes Dev. 2002 Jun 15;16(12):1466-71 [12080085.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47014-21 [12354771.001]
  • [Cites] Rev Med Virol. 2003 May-Jun;13(3):173-84 [12740832.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):19575-8 [12639949.001]
  • [Cites] J Virol. 2003 Jun;77(12):6761-8 [12767996.001]
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9361-74 [14645546.001]
  • [Cites] J Virol. 2004 Mar;78(5):2609-14 [14963167.001]
  • [Cites] Mol Interv. 2002 Jul;2(4):229-43 [14993394.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):713-23 [15023341.001]
  • [Cites] Physiology (Bethesda). 2004 Aug;19:176-82 [15304631.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38325-30 [15247271.001]
  • [Cites] J Lab Clin Med. 1971 Dec;78(6):1006 [5131833.001]
  • [Cites] South Med J. 1981 May;74(5):585-9 [6787716.001]
  • [Cites] Mol Cell Biol. 1992 Dec;12(12):5447-54 [1448077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):3928-32 [8387202.001]
  • [Cites] J Biol Chem. 1993 Oct 15;268(29):21513-8 [8408001.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] J Biol Chem. 1996 Jul 26;271(30):17771-8 [8663540.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4604-13 [8756616.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] Am J Physiol. 1996 Oct;271(4 Pt 1):C1172-80 [8897823.001]
  • [Cites] J Biol Chem. 1996 Dec 20;271(51):32529-37 [8955077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] Genes Dev. 1997 Jan 1;11(1):72-82 [9000051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4273-8 [9113979.001]
  • [Cites] Mech Dev. 1997 Apr;63(1):51-60 [9178256.001]
  • [Cites] J Biol Chem. 1997 Sep 5;272(36):22642-7 [9278421.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):7987-92 [9653127.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] J Virol. 1998 Oct;72(10):8309-15 [9733875.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] Gene Expr. 1998;7(3):205-13 [9840812.001]
  • [Cites] J Virol. 1999 Feb;73(2):1438-46 [9882349.001]
  • [Cites] J Gen Virol. 1999 Jan;80 ( Pt 1):83-90 [9934688.001]
  • [Cites] J Virol. 1999 Mar;73(3):1909-17 [9971770.001]
  • [Cites] J Biol Chem. 1999 Mar 5;274(10):6519-25 [10037745.001]
  • [Cites] Virology. 1999 Apr 25;257(1):84-94 [10208923.001]
  • [Cites] J Virol. 1999 Jun;73(6):4786-93 [10233939.001]
  • (PMID = 16809309.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Viral Proteins; EC 2.7.- / Phosphotransferases; EC 3.1.- / Exonucleases
  • [Other-IDs] NLM/ PMC1489055
  •  go-up   go-down


54. Yanagisawa Y, Sato Y, Asahi-Ozaki Y, Ito E, Honma R, Imai J, Kanno T, Kano M, Akiyama H, Sata T, Shinkai-Ouchi F, Yamakawa Y, Watanabe S, Katano H: Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma. J Pathol; 2006 Aug;209(4):464-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effusion and solid lymphomas have distinctive gene and protein expression profiles in an animal model of primary effusion lymphoma.
  • Lymphoma usually forms solid tumours in patients, and high expression levels of adhesion molecules are observed in these tumours.
  • However, Kaposi's sarcoma-associated herpesvirus (KSHV)-related primary effusion lymphoma (PEL) does not form solid tumours and adhesion molecule expression is suppressed in the cells.
  • Inoculation of a KSHV-associated PEL cell line into the peritoneal cavity of severe combined immunodeficiency mice resulted in the formation of effusion and solid lymphomas in the peritoneal cavity.
  • Proteomics using two-dimensional difference gel electrophoresis and DNA microarray analyses identified 14 proteins and 105 genes, respectively, whose expression differed significantly between effusion and solid lymphomas.
  • Five genes were identified as having similar expression profiles to that of lymphocyte function-associated antigen 1, an important adhesion molecule in leukocytes.
  • Among these, coronin 1A, an actin-binding protein, was identified as a molecule showing high expression in solid lymphoma by both DNA microarray and proteomics analyses.
  • Western and northern blotting showed that coronin 1A was predominantly expressed in solid lymphomas.
  • Moreover, KSHV-encoded lytic proteins, including viral interleukin-6, were highly expressed in effusion lymphoma compared with solid lymphoma.
  • These data demonstrate that effusion and solid lymphomas possess distinctive gene and protein expression profiles in our mouse model, and suggest that differences in gene and protein expression between effusion and solid lymphomas may be associated with the formation of effusion lymphoma or invasive features of solid lymphoma.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / virology. Gene Expression Regulation, Viral. Herpesvirus 8, Human. Lymphoma, AIDS-Related / genetics. Sarcoma, Kaposi / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. DNA, Viral / analysis. Electrophoresis, Gel, Two-Dimensional. Gene Expression Profiling. Humans. Lymphocyte Function-Associated Antigen-1 / genetics. Mice. Mice, SCID. Models, Animal. Oligonucleotide Array Sequence Analysis. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / virology. Proteomics. Reverse Transcriptase Polymerase Chain Reaction. Viral Proteins / analysis


55. Lo Re V 3rd, Guaraldi G, Leonard MB, Localio AR, Lin J, Orlando G, Zirilli L, Rochira V, Kostman JR, Tebas P: Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS; 2009 Oct 23;23(16):2191-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.
  • OBJECTIVE: Few studies have examined the impact of viral hepatitis on bone mineral density (BMD), and none have done so among HIV-infected patients.
  • Our objective was to determine whether viral hepatitis was associated with low BMD in HIV.
  • DESIGN: : A cross-sectional study among 1237 HIV-infected patients (625 with viral hepatitis).
  • RESULTS: Mean BMD Z-scores were lower among hepatitis-coinfected women at the lumbar spine {-0.15 versus +0.29; difference = -0.44 [95% confidence Interval (CI) -0.65 to -0.23]; P < 0.001} and femoral neck [-0.64 versus -0.39; difference = -0.25 (95% CI -0.44 to -0.06); P = 0.009] compared with HIV-monoinfected women.
  • After adjustment for age, BMI, duration of HIV, antiretroviral use, physical activity, and smoking, viral hepatitis was associated with low BMD among women (adjusted odds ratio 2.87, 95% CI 1.31-6.29) but not men (adjusted odds ratio 1.19, 95% CI 0.74-1.91).
  • Coinfected women had lower mean parathyroid hormone (60.1 versus 68.1 pg/ml; P = 0.02) but similar mean 25-hydroxyvitamin D (19.1 versus 19.6 ng/ml; P = 0.6) and osteocalcin (3.0 versus 3.2 ng/ml; P = 0.8) concentrations than HIV-monoinfected women.
  • CONCLUSION: Viral hepatitis was associated with a higher risk of low BMD among HIV-infected women but not men.

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2000 Jul 26;284(4):450-6 [10904508.001]
  • [Cites] Dig Dis Sci. 2000 Jul;45(7):1392-9 [10961720.001]
  • [Cites] Hepatology. 2001 Jan;33(1):301-7 [11124849.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Sep;16(9):1022-7 [11595067.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2695-701 [11723115.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):831-7 [11833007.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):941-66 [12949738.001]
  • [Cites] Ann Epidemiol. 2003 Nov;13(10):692-7 [14599733.001]
  • [Cites] J Mol Endocrinol. 2003 Dec;31(3):609-20 [14664720.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2004 Mar;48(1):39-48 [15195003.001]
  • [Cites] JAMA. 2004 Jul 14;292(2):191-201 [15249568.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4325-30 [15356028.001]
  • [Cites] Lancet. 1993 Jan 9;341(8837):72-5 [8093403.001]
  • [Cites] Gastroenterology. 1995 Jan;108(1):276-83 [7806050.001]
  • [Cites] Demography. 1995 Aug;32(3):459-70 [8829977.001]
  • [Cites] J Gastroenterol Hepatol. 1996 May;11(5):417-21 [8743912.001]
  • [Cites] J Gastroenterol. 1996 Oct;31(5):669-78 [8887033.001]
  • [Cites] J Hepatol. 1997 Jan;26(1):1-5 [9147999.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1997 Mar;9(3):283-6 [9096431.001]
  • [Cites] Hepatology. 1998 Sep;28(3):695-9 [9731561.001]
  • [Cites] Hepatology. 1999 Mar;29(3):908-14 [10051497.001]
  • [Cites] Ann Intern Med. 1999 Mar 16;130(6):461-70 [10075613.001]
  • [Cites] Calcif Tissue Int. 1999 Aug;65(2):91-9 [10430638.001]
  • [Cites] Arch Intern Med. 2004 Nov 22;164(21):2349-54 [15557414.001]
  • [Cites] Clin Infect Dis. 2006 Jan 1;42(1):108-14 [16323100.001]
  • [Cites] AIDS. 2006 Jan 2;20(1):49-57 [16327319.001]
  • [Cites] HIV Clin Trials. 2006 May-Jun;7(3):97-106 [16880166.001]
  • [Cites] Arch Intern Med. 2006 Aug 14-28;166(15):1632-41 [16908797.001]
  • [Cites] AIDS. 2006 Nov 14;20(17):2165-74 [17086056.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Sep;93(9):3499-504 [18593764.001]
  • [Cites] Ann Epidemiol. 2008 Nov;18(11):847-50 [18809342.001]
  • (PMID = 19779322.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / K01 AI070001; United States / NIAID NIH HHS / AI / P30-AI045008; United States / PHS HHS / / U01-IA069467; United States / NIAID NIH HHS / AI / P30 AI045008; United States / NIAID NIH HHS / AI / AI070001-01A1; United States / NIAID NIH HHS / AI / K01 AI070001-01A1; United States / NIAID NIH HHS / AI / K01-AI070001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS182885; NLM/ PMC2837269
  •  go-up   go-down


56. Widney DP, Gui D, Popoviciu LM, Said JW, Breen EC, Huang X, Kitchen CM, Alcantar JM, Smith JB, Detels R, Martínez-Maza O: Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma. AIDS Res Treat; 2010;2010:164586
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma.
  • CXCL13/CXCR5 are expressed, and may play a role, in some non-AIDS-associated B cell tumors.
  • Objective. To determine if CXCL13/CXCR5 are associated with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL).
  • Methods. Serum CXCL13 levels were measured by ELISA in 46 subjects who developed AIDS-NHL in the Multicenter AIDS Cohort Study and in controls.
  • The expression or function of CXCL13 and CXCR5 was examined on primary AIDS-NHL specimens or AIDS-NHL cell lines.
  • Results. Serum CXCL13 levels were significantly elevated in the AIDS-NHL group compared to controls.
  • All primary AIDS-NHL specimens showed CXCR5 expression and most also showed CXCL13 expression.
  • AIDS-NHL cell lines expressed CXCR5 and showed chemotaxis towards CXCL13.
  • Conclusions. CXCL13/CXCR5 are expressed in AIDS-NHL and could potentially be involved in its biology.
  • CXCL13 may have potential as a biomarker for AIDS-NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2008 Aug;215(4):431-44 [18561120.001]
  • [Cites] J Neuroimmunol. 2008 Jul 31;198(1-2):106-12 [18539341.001]
  • [Cites] Blood. 2009 May 7;113(19):4604-13 [19228923.001]
  • [Cites] Am J Epidemiol. 1987 Aug;126(2):310-8 [3300281.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1099-107 [8099121.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1037-47 [8978608.001]
  • [Cites] Blood. 1997 Jul 15;90(2):520-5 [9226150.001]
  • [Cites] J Exp Med. 1998 Feb 16;187(4):655-60 [9463416.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):799-803 [9486651.001]
  • [Cites] Oncology (Williston Park). 2001 Apr;15(4):439-48; discussion 448-9 [11346932.001]
  • [Cites] Curr Opin Oncol. 2002 Sep;14(5):528-32 [12192272.001]
  • [Cites] Ophthalmology. 2003 Feb;110(2):421-6 [12578791.001]
  • [Cites] Tumour Biol. 2003 Mar-Apr;24(2):82-93 [12853703.001]
  • [Cites] Breast Dis. 2004;20:137-43 [15687714.001]
  • [Cites] J Natl Cancer Inst. 1991 May 15;83(10):695-701 [2023270.001]
  • [Cites] Blood. 1995 Jun 15;85(12):3423-30 [7780129.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 27;235(3):576-81 [9207199.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Blood Rev. 1999 Sep;13(3):147-50 [10527266.001]
  • [Cites] Immunology. 2000 Feb;99(2):266-71 [10692046.001]
  • [Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]
  • [Cites] Immunol Rev. 2000 Aug;176:181-93 [11043777.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar 30;282(2):369-75 [11401467.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1270-5 [11423258.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5028-37 [11431337.001]
  • [Cites] Blood. 2002 Jan 1;99(1):207-12 [11756173.001]
  • [Cites] Nature. 2002 Mar 7;416(6876):94-9 [11882900.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3106-12 [12036921.001]
  • [Cites] J Leukoc Biol. 2002 Jul;72(1):1-8 [12101256.001]
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] J Virol. 2003 Feb;77(3):2271-5 [12525664.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86 [12626353.001]
  • [Cites] Blood. 2004 Jul 15;104(2):502-8 [15001469.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1952-60 [15213097.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):489-96 [15349823.001]
  • [Cites] AIDS. 2005 Oct 14;19(15):1711-2 [16184051.001]
  • [Cites] J Interferon Cytokine Res. 2005 Nov;25(11):702-6 [16318584.001]
  • [Cites] Acta Neuropathol. 2007 Sep;114(3):271-6 [17641901.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3316-25 [17652619.001]
  • [Cites] Immunity. 2007 Aug;27(2):190-202 [17723214.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3200-10 [18184868.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4401-10 [18780835.001]
  • (PMID = 21490903.001).
  • [ISSN] 2090-1259
  • [Journal-full-title] AIDS research and treatment
  • [ISO-abbreviation] AIDS Res Treat
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI035042; United States / NIAID NIH HHS / AI / U01 AI037984; United States / NCI NIH HHS / CA / R01 CA073475; United States / NIAID NIH HHS / AI / U01 AI037613; United States / NCRR NIH HHS / RR / M01 RR000722; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / UM1 AI035043; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA057152; United States / NIAID NIH HHS / AI / U01 AI035043; United States / NIAID NIH HHS / AI / U01 AI035040; United States / NIAID NIH HHS / AI / U01 AI035039
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3065842
  •  go-up   go-down


57. Cooper CM, James K, Wilks RJ: HTLV-1 related knowledge, attitude and behaviour patterns among mothers who participated in the Jamaica Breastfeeding Intervention Study (1996-2000). West Indian Med J; 2010 Jan;59(1):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1 related knowledge, attitude and behaviour patterns among mothers who participated in the Jamaica Breastfeeding Intervention Study (1996-2000).
  • Human T-cell Lymphotropic Virus type-1 (HTLV-1), the first human retrovirus associated with a malignant disease, is endemic in Jamaica.
  • A minority was aware of HTLV-1 associated diseases: Adult T-cell lymphoma/leukaemia (ATL) -30.7%; Tropical Spastic Paraparesis (TSP) -42%; Infective dermatitis -42%).
  • Ten (11.4%) believed that HTLV-1 infection can cause HIV/AIDS and only 33% knew that there was no cure for the virus.
  • [MeSH-minor] Adult. Chi-Square Distribution. Cross-Sectional Studies. Demography. Female. Focus Groups. Health Education. Humans. Infectious Disease Transmission, Vertical. Jamaica / epidemiology. Male. Middle Aged. Regression Analysis. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Breastfeeding.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931911.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Jamaica
  •  go-up   go-down


58. Carbone A, Gloghini A, Vaccher E, Marchetti G, Gaidano G, Tirelli U: KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype. J Clin Pathol; 2005 Oct;58(10):1039-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KSHV/HHV-8 associated lymph node based lymphomas in HIV seronegative subjects. Report of two cases with anaplastic large cell morphology and plasmablastic immunophenotype.
  • BACKGROUND: Kaposi sarcoma associated herpesvirus (KSHV)/human herpesvirus 8 (HHV-8) associated lymphomas, which often develop in human immunodeficiency virus (HIV) infected patients with advanced AIDS, present predominantly as primary effusion lymphoma (PEL) or, less frequently, as "solid" extracavitary based lymphomas, associated with serous effusions.
  • These last lymphomas, also called "solid PEL", have been reported before the development of an effusion lymphoma and after resolution of PEL.
  • Interestingly, KSHV/HHV-8 associated lymphomas that present as solid or extracavitary based lesions in HIV seropositive patients without serous effusions have been reported recently.
  • METHODS/RESULTS: This paper provides evidence for the existence of a previously undescribed KSHV/HHV-8 associated lymphoma in HIV seronegative patients without serous effusions.
  • These lymphomas exhibit a predilection for the lymph nodes and display anaplastic large cell morphology.
  • B and T cell associated antigens and other commonly used lymphoid markers were absent or weakly demonstrable in a fraction of the tumour cells.
  • CONCLUSIONS: Analysis of viral infection and immunohistological studies are of primary importance to define this lymph node based KSHV/HHV-8 associated lymphoma with anaplastic large cell morphology and plasmablastic immunophenotype occurring in HIV seronegative patients without serous effusions.
  • [MeSH-major] Herpesviridae Infections / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma, Large B-Cell, Diffuse / virology
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. HIV Seronegativity. Humans. Immunophenotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Jan;13(1):77-85 [10658913.001]
  • [Cites] Int J Cancer. 1997 Nov 14;73(4):562-9 [9389573.001]
  • [Cites] Leuk Lymphoma. 1999 Oct;35(3-4):379-87 [10706463.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):753-5 [10782162.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2069-73 [10979949.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):32-8 [11227070.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] AIDS Patient Care STDS. 2002 Apr;16(4):139-45 [12015867.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] Hum Pathol. 2003 Jun;34(6):630 [12827623.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] J Clin Virol. 2003 Oct;28(2):155-64 [12957185.001]
  • [Cites] Am J Surg Pathol. 2004 May;28(5):693-7 [15105661.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Dec;8(4):293-312 [9620643.001]
  • [Cites] N Engl J Med. 1998 Aug 13;339(7):444-9 [9700178.001]
  • [Cites] Br J Haematol. 1998 Sep;102(4):1081-9 [9734661.001]
  • [Cites] Lab Invest. 1998 Dec;78(12):1637-42 [9881964.001]
  • [Cites] Semin Cancer Biol. 1999 Jun;9(3):165-74 [10343068.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):992-4 [10435572.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] Hum Pathol. 2002 Aug;33(8):846-9 [12203218.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1363-7 [12360052.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Dec;21(12):831-44 [12525917.001]
  • [Cites] Blood. 2003 May 15;101(10):4115-21 [12531789.001]
  • [Cites] J Clin Pathol. 1994 May;47(5):418-22 [7517959.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):53-7 [8686762.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):318-23 [8759892.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] AIDS. 1996 Aug;10(9):941-9 [8853726.001]
  • [Cites] Blood. 1996 Oct 15;88(8):3124-8 [8874212.001]
  • [Cites] Ann Intern Med. 1996 Nov 15;125(10):822-5 [8928989.001]
  • [Cites] J Infect Dis. 1997 May;175(5):1198-201 [9129085.001]
  • [Cites] Am J Surg Pathol. 1997 Jun;21(6):719-24 [9199651.001]
  • [Cites] Int J Cancer. 1997 Oct 9;73(2):303-4 [9335459.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • (PMID = 16189148.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  • [Other-IDs] NLM/ PMC1770735
  •  go-up   go-down


59. Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O'Mahony D, Lee MJ, Trepel J, Waldmann TA, Janik JE, Brady JN: Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood; 2009 Apr 23;113(17):4016-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
  • Adult T-cell leukemia/lymphoma (ATL) is an aggressive and fatal disease.
  • We have examined 32 patients with smoldering, chronic, lymphoma and acute leukemia using Affymetrix HG-U133A2.0 arrays.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):177-85 [9720727.001]
  • [Cites] Vet Immunol Immunopathol. 1998 Jul 31;64(3):207-18 [9730217.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1341-9 [10022816.001]
  • [Cites] Immunol Rev. 2004 Dec;202:139-56 [15546391.001]
  • [Cites] Cell Cycle. 2004 Sep;3(9):1121-3 [15326382.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):119-29 [15798092.001]
  • [Cites] Immunol Res. 2005;31(3):231-42 [15888914.001]
  • [Cites] Cancer Sci. 2005 May;96(5):249-55 [15904464.001]
  • [Cites] FASEB J. 2005 Jul;19(9):1125-7 [15985535.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3380-2 [16076875.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):103-5 [15979704.001]
  • [Cites] Front Biosci. 2006;11:1508-21 [16368533.001]
  • [Cites] Blood. 2006 Jan 15;107(2):716-24 [16174765.001]
  • [Cites] Leukemia. 2006 Apr;20(4):590-8 [16453001.001]
  • [Cites] Immunity. 2006 May;24(5):506-7 [16713967.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4880-7 [16497974.001]
  • [Cites] J Interferon Cytokine Res. 2006 Jul;26(7):473-83 [16800786.001]
  • [Cites] Curr Drug Metab. 2006 Aug;7(6):599-612 [16918315.001]
  • [Cites] J Virol. 2006 Nov;80(21):10497-505 [16920823.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):49-60 [17275177.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):61-70 [18075512.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1695-700 [11080812.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):5228-34 [11083865.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4484-96 [11494144.001]
  • [Cites] Virus Res. 2001 Oct 30;78(1-2):79-92 [11520582.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16768-74 [11875076.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1069-85 [12040438.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3562-71 [12068005.001]
  • [Cites] Blood. 2002 Aug 1;100(3):982-90 [12130512.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15632-7 [12438652.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2249-55 [12613509.001]
  • [Cites] J Neurovirol. 2003 Apr;9(2):228-35 [12707853.001]
  • [Cites] Nutr Cancer. 2002;44(2):193-201 [12734068.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5141-9 [12910251.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6453-7 [14559836.001]
  • [Cites] Adv Cancer Res. 2003;89:69-132 [14587871.001]
  • [Cites] Int J Cancer. 2004 May 10;109(6):875-81 [15027121.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1105-11 [15176993.001]
  • [Cites] Blood. 2004 Aug 1;104(3):802-9 [15090453.001]
  • [Cites] Int J Hematol. 2004 Jul;80(1):52-8 [15293568.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5578-86 [15313894.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1490-7 [15155458.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2527-39 [15353305.001]
  • [Cites] J Clin Oncol. 1988 Jul;6(7):1088-97 [2899140.001]
  • [Cites] Blood. 1988 Nov;72(5):1805-16 [2846094.001]
  • [Cites] Int J Cancer. 1989 Feb 15;43(2):250-3 [2917802.001]
  • [Cites] Jpn J Cancer Res. 1989 Mar;80(3):191-5 [2498254.001]
  • [Cites] Eur J Immunol. 1991 Aug;21(8):1879-85 [1831129.001]
  • [Cites] Blood. 1992 Jan 15;79(2):477-80 [1730092.001]
  • [Cites] Leuk Res. 1993 Feb;17(2):157-66 [8429692.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Immunity. 1995 Jan;2(1):89-100 [7600304.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 7;766:235-44 [7486666.001]
  • (PMID = 19131553.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / BIRC5 protein, human; 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Boronic Acids; 0 / DNA-Binding Proteins; 0 / Immunoglobulin G; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Pyrazines; 0 / TCF4 protein, human; 0 / Transcription Factors; 69G8BD63PP / Bortezomib; CUJ2MVI71Y / daclizumab
  • [Other-IDs] NLM/ PMC2673128
  •  go-up   go-down


60. Trevaskis NL, Charman WN, Porter CJ: Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation? Mol Pharm; 2010 Dec 6;7(6):2297-309
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphocytes are central to the progression of autoimmune disease, transplant rejection, leukemia, lymphoma and lymphocyte-resident viral diseases such as HIV/AIDs.
  • Strategies to target drug treatments to lymphocytes, therefore, represent an opportunity to enhance therapeutic outcomes in disease states where many current treatment regimes are incompletely effective and promote significant toxicities.
  • The current data suggest that complementary drug design and delivery strategies that combine highly lipophilic, lymphotropic drug candidates with lymph-directing formulations provide enhanced selectivity, potency and therapeutic potential for drug candidates with lymphocyte associated targets.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DDT .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mol Pharm. 2011 Dec 5;8(6):2484
  • (PMID = 20958081.001).
  • [ISSN] 1543-8392
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Indoles; 0 / JHW 015; 0 / Mitogens; 0 / Phenanthrenes; CIW5S16655 / DDT; Q2OS4303HZ / halofantrine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


61. Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA, Cullen BR: Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol; 2010 Nov;84(22):11670-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LCL formation serves as a model for lymphomagenesis, and LCLs are phenotypically similar to EBV-positive diffuse large B-cell lymphomas (DLBCLs), which represent a common AIDS-associated malignancy.
  • B-cell infection by EBV induces the expression of several cellular microRNAs (miRNAs), most notably miR-155, which is overexpressed in many tumors and can induce B-cell lymphomas when overexpressed in animals.
  • In contrast, three other B-cell lymphoma lines, including two EBV-positive Burkitt's lymphoma cell lines, grew normally in the absence of miR-155 function.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2006 Jun;80(11):5321-6 [16699012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] J Gen Virol. 2006 Oct;87(Pt 10):2885-90 [16963746.001]
  • [Cites] Science. 2007 Apr 27;316(5824):604-8 [17463289.001]
  • [Cites] Science. 2007 Apr 27;316(5824):608-11 [17463290.001]
  • [Cites] Nucleic Acids Res. 2007;35(10):e73 [17478510.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1156-61 [17487835.001]
  • [Cites] Nat Methods. 2007 Sep;4(9):721-6 [17694064.001]
  • [Cites] J Virol. 2007 Dec;81(23):12836-45 [17881434.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1096-9 [18075594.001]
  • [Cites] Immunity. 2007 Dec;27(6):847-59 [18055230.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Feb;181(1):8-15 [18262046.001]
  • [Cites] J Pathol. 2008 May;215(1):13-20 [18348159.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):407-15 [18392026.001]
  • [Cites] J Virol. 2008 Jun;82(11):5295-306 [18367535.001]
  • [Cites] Immunity. 2008 May;28(5):621-9 [18450484.001]
  • [Cites] Immunity. 2008 May;28(5):630-8 [18455451.001]
  • [Cites] Oncogene. 2008 Jul 17;27(31):4373-9 [18372920.001]
  • [Cites] Nature. 2008 Aug 7;454(7205):780-3 [18596690.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8164-72 [18829576.001]
  • [Cites] J Virol. 2008 Nov;82(21):10436-43 [18753206.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Dec 12;377(2):579-83 [18926796.001]
  • [Cites] Nucleic Acids Res. 2008 Nov;36(20):6608-19 [18940871.001]
  • [Cites] J Virol. 2008 Dec;82(24):12213-20 [18842708.001]
  • [Cites] Virology. 2008 Dec 20;382(2):257-66 [18950829.001]
  • [Cites] J Virol. 2009 Jan;83(1):489-92 [18945769.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] J Virol. 2009 Apr;83(7):3333-41 [19144710.001]
  • [Cites] Leukemia. 2009 Apr;23(4):807-10 [18987659.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7113-8 [19359473.001]
  • [Cites] Genes Dev. 2009 May 15;23(10):1151-64 [19451215.001]
  • [Cites] J Virol. 2009 Dec;83(23):12009-17 [19759154.001]
  • [Cites] RNA Biol. 2009 Nov-Dec;6(5):541-5 [19901530.001]
  • [Cites] J Virol. 2010 Jan;84(2):695-703 [19889781.001]
  • [Cites] EMBO Mol Med. 2009 Aug;1(5):288-95 [19890474.001]
  • [Cites] Science. 2010 Jan 8;327(5962):198-201 [19965718.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3111-6 [20133617.001]
  • [Cites] Cell. 2010 Apr 2;141(1):129-41 [20371350.001]
  • [Cites] J Virol. 2010 May;84(10):5229-37 [20219912.001]
  • [Cites] J Virol. 2010 Jul;84(13):6318-27 [20427544.001]
  • [Cites] Mol Cell. 2002 Jun;9(6):1327-33 [12086629.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Science. 2004 Apr 30;304(5671):734-6 [15118162.001]
  • [Cites] Nature. 1988 Sep 8;335(6186):181-3 [3412474.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2657-64 [2548084.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 [15738415.001]
  • [Cites] J Pathol. 2005 Oct;207(2):243-9 [16041695.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):103-6 [16175574.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Feb;45(2):147-53 [16235244.001]
  • [Cites] RNA. 2006 May;12(5):733-50 [16540699.001]
  • [Cites] PLoS Pathog. 2006 Mar;2(3):e23 [16557291.001]
  • (PMID = 20844043.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI007392; United States / NIAID NIH HHS / AI / P30-AI045008; United States / NIAID NIH HHS / AI / R01-AI067968; United States / NIAID NIH HHS / AI / R01 AI067968; United States / NCI NIH HHS / CA / T32-CA0009111; United States / NIAID NIH HHS / AI / P30 AI045008; United States / NCI NIH HHS / CA / T32 CA009111; United States / NIAID NIH HHS / AI / T32-AI007392; United States / NCI NIH HHS / CA / K99 CA137860-01A1; United States / NCI NIH HHS / CA / K99 CA137860; United States / NCI NIH HHS / CA / K99-CA137860
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN155 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2977875
  •  go-up   go-down


62. Waters L, Stebbing J, Mandalia S, Young AM, Nelson M, Gazzard B, Bower M: Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort study. Int J Cancer; 2005 Aug 10;116(1):161-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort study.
  • Immunosuppression induced by the human immunodeficiency virus (HIV) increases the risk of developing non-Hodgkin's lymphoma (NHL).
  • As the hepatitis C virus (HCV) has been implicated in the development of B cell lymphomas, we compared the incidence of systemic NHL during HIV infection compared to HIV and HCV co-infection.
  • The incidence of systemic NHL was 6.9 of 10(4) patient years during HIV infection compared to 7.1 of 10(4) patient years during HIV alone (p = 0.9).
  • In this immunocompromised patient population, there was no association between HCV infection and an increased risk of lymphoma.
  • [MeSH-major] HIV Infections / complications. Hepatitis C / complications. Lymphoma, AIDS-Related / complications. Lymphoma, Non-Hodgkin / complications

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15756687.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Stewart B: HIV-associated Burkitt lymphoma: case presentations and review. AIDS Read; 2006 Dec;16(12):647-8, 654-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated Burkitt lymphoma: case presentations and review.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / drug therapy. HIV Infections

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17195323.001).
  • [ISSN] 1053-0894
  • [Journal-full-title] The AIDS reader
  • [ISO-abbreviation] AIDS Read
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


64. Bandera A, Trabattoni D, Pacei M, Fasano F, Suardi E, Cesari M, Marchetti G, Pogliani EM, Franzetti F, Clerici M, Gori A: Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response. PLoS One; 2008;3(10):e3616
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Reduced CD4 T lymphocytes counts can be observed in HIV infection and in patients undergoing autologous haematopoietic stem cell transplantation (ASCT).
  • Nevertheless, whereas opportunistic infections (OI) are frequent in HIV-infected individuals with low cell counts, OI are uncommon in ASCT patients.
  • METHODOLOGY/PRINCIPAL FINDINGS: To verify whether this observation could be secondary to intrinsic HIV-correlated T cell defects, we performed in-depth immunologic analyses in 10 patients with comparable CD4 counts in whom lymphopenia was secondary either to HIV-infection or ASCT-associated immunosuppressive therapy and compared them to age-matched healthy subjects.
  • Thus, a low percentage of CCR7+ CD4+ T cells and a compensative expansion of CD45RA-CCR7- CD4+ T cells, a reduced IL-2/IFN-gamma cytokine production and impaired recall antigens-specific proliferative responses were detected both in ASCT and HIV patients.
  • The presence of strong CD8 T cells mediated immune responses justifies the more favorable clinical outcome of ASCT compared to HIV patients.
  • CONCLUSION/SIGNIFICANCE: These results indicate that CD8 T cells maturation and functions can be observed even in the face of a profound impairment of CD4+ T lymphocytes in ASCT but not in HIV patients.
  • Primary HIV-associated CD8 defects or an imprinting by an intact CD4 T cell system in ASCT could justify these results.
  • [MeSH-minor] Adult. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / physiology. Case-Control Studies. Cell Differentiation / immunology. Cell Proliferation. Cross-Sectional Studies. HIV Infections / immunology. HIV Infections / pathology. HIV-1. Humans. Middle Aged. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] MMWR CDC Surveill Summ. 1999 Apr 16;48(2):1-22 [12412613.001]
  • [Cites] J Immunol. 2007 Aug 15;179(4):2627-33 [17675526.001]
  • [Cites] Ann Hematol. 2003 May;82(5):263-70 [12739062.001]
  • [Cites] Eur J Immunol. 2003 Dec;33(12):3225-31 [14635030.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1909-22 [14676302.001]
  • [Cites] Blood. 2004 Jan 1;103(1):20-32 [12969978.001]
  • [Cites] Blood. 2004 Feb 1;103(3):966-72 [12958069.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):3337-47 [14978142.001]
  • [Cites] Lancet. 2004 Mar 13;363(9412):863-6 [15031033.001]
  • [Cites] AIDS. 2004 Apr 9;18(6):859-69 [15060433.001]
  • [Cites] Nature. 1989 Jun 1;339(6223):383-5 [2524668.001]
  • [Cites] J Clin Invest. 1989 Dec;84(6):1892-9 [2574188.001]
  • [Cites] Transplantation. 1995 Oct 15;60(7):672-8 [7570975.001]
  • [Cites] Blood. 1997 May 15;89(10):3700-7 [9160675.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1471-90 [9716573.001]
  • [Cites] Eur J Immunol. 2004 Dec;34(12):3525-33 [15484193.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):1037-45 [15634928.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3158-63 [15749843.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3793-801 [15809447.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):102-8 [16405430.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):63-75 [10880527.001]
  • [Cites] Clin Infect Dis. 2001 Feb 15;32(4):546-51 [11181116.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):106-11 [11242051.001]
  • [Cites] Bone Marrow Transplant. 2001 Mar;27(5):525-9 [11313687.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1381-7 [12149221.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):1061-8 [12368910.001]
  • [Cites] Clin Immunol. 2006 Jun;119(3):261-71 [16426894.001]
  • [Cites] Leuk Lymphoma. 2007 Mar;48(3):506-12 [17454590.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3756-64 [12516570.001]
  • (PMID = 18974880.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2570790
  •  go-up   go-down


65. Mallik S, Talapatra K, Goswami J: AIDS: a radiation oncologist's perspective. J Cancer Res Ther; 2010 Oct-Dec;6(4):432-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS: a radiation oncologist's perspective.
  • While HIV is often associated with tuberculosis and a number of opportunistic infections, the spectrum of diseases of patients with HIV infection encompasses a number of malignancies as well.
  • Typically, these are the AIDS-defining malignancies, though other malignancies also comprise a significant caseload.
  • Radiotherapy plays an integral part in anti-cancer treatment and its tolerance and efficacy in HIV+ patients are therefore important.
  • In some cases, like primary central nervous system lymphoma (PCNSL), the occurrence of the malignancy itself is tied to the patient's immunity with increased incidence in patients with CD4 counts less than 50/mm 3.
  • In general, standard radiotherapy and concomitant chemo-radiotherapy protocols should be used wherever possible, so as not to compromise disease control.
  • Local control and disease-specific survival rates in HIV patients are no worse than in HIV?
  • In certain situations like cervical intraepithelial neoplasia CIN, HAART itself is associated with disease regression.
  • The question of increased radiosensitivity in HIV patients remains unresolved in most diseases and there are sparse data with regard to non-HIV associated malignancies in these patients.
  • Greater caution and emphasis on good supportive care and HAART would appear to be essential when treating the malignancies in HIV+ patients with standard anti-cancer regimens.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21358076.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


66. Manabe M, Yoshii Y, Mukai S, Sakamoto E, Kanashima H, Shirano M, Goto T, Kubo Y, Fukushima H, Inoue T, Teshima H: BK virus-associated nephropathy in an HIV-positive patient with gingival plasmablastic lymphoma. Int J Hematol; 2010 Jul;92(1):208-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BK virus-associated nephropathy in an HIV-positive patient with gingival plasmablastic lymphoma.
  • [MeSH-major] HIV Seropositivity / complications. Kidney Diseases / virology. Lymphoma, Large-Cell, Immunoblastic / complications


67. Laney AS, Peters JS, Manzi SM, Kingsley LA, Chang Y, Moore PS: Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection. J Clin Microbiol; 2006 Oct;44(10):3734-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection.
  • The ability to readily and accurately diagnose Kaposi's sarcoma-associated herpesvirus (KSHV, or human herpesvirus 8) infection in individuals remains a demanding task.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Nov;23(11):1393-400 [10555008.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2826-9 [9326251.001]
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):213-24 [10670545.001]
  • [Cites] Clin Infect Dis. 2000 Apr;30 Suppl 1:S72-6 [10770915.001]
  • [Cites] Transplantation. 2000 May 15;69(9):1776-9 [10830210.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):346-54 [10836758.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2174-80 [10834972.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2355-7 [11001882.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3279-81 [11050015.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]
  • [Cites] J Clin Microbiol. 1998 Jun;36(6):1574-7 [9620379.001]
  • [Cites] Transplant Proc. 1998 Aug;30(5):2095-6 [9723403.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1358-63 [9801396.001]
  • [Cites] J Infect Dis. 1998 Dec;178(6):1610-5 [9815212.001]
  • [Cites] Leukemia. 1999 May;13(5):664-70 [10374868.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):1010-7 [10479125.001]
  • [Cites] Chest. 2005 Mar;127(3):762-7 [15764755.001]
  • [Cites] Transfusion. 2005 Apr;45(4):500-3 [15819669.001]
  • [Cites] AIDS. 2005 Jun 10;19(9):953-60 [15905677.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1378-85 [11070102.001]
  • [Cites] N Engl J Med. 2001 Mar 1;344(9):637-43 [11228278.001]
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):506-8 [11158097.001]
  • [Cites] Br J Haematol. 2001 May;113(2):425-8 [11380409.001]
  • [Cites] J Med Virol. 2001 Sep;65(1):123-32 [11505454.001]
  • [Cites] Clin Diagn Lab Immunol. 2001 Sep;8(5):913-21 [11527803.001]
  • [Cites] Transplantation. 2001 Oct 15;72(7):1319-20 [11602862.001]
  • [Cites] J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):295-9 [11873080.001]
  • [Cites] Leuk Lymphoma. 2002 Mar;43(3):517-22 [12002754.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2217-9 [12037090.001]
  • [Cites] J Infect Dis. 2003 Jan 1;187(1):12-8 [12508141.001]
  • [Cites] Pediatr Transplant. 2003 Feb;7(1):1-3 [12581319.001]
  • [Cites] Nat Med. 2003 May;9(5):554-61 [12692543.001]
  • [Cites] Nat Med. 2003 May;9(5):506-8 [12692545.001]
  • [Cites] Clin Infect Dis. 2003 Aug 15;37(4):606-7; author reply 607 [12905148.001]
  • [Cites] Transfusion. 2003 Sep;43(9):1260-8 [12919429.001]
  • [Cites] Liver Transpl. 2004 Feb;10(2):295-300 [14762870.001]
  • [Cites] AIDS. 2004 Sep 3;18(13):1819-26 [15316343.001]
  • [Cites] J Med Virol. 2004 Oct;74(2):202-6 [15332267.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] N Engl J Med. 1996 Jul 25;335(4):233-41 [8657239.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Lancet. 1996 Sep 28;348(9031):858-61 [8826812.001]
  • [Cites] AIDS. 1996 Feb;10(2):175-80 [8838705.001]
  • [Cites] Lancet. 1997 Mar 1;349(9052):609-11 [9057733.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):696-701 [10655369.001]
  • (PMID = 17021103.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA067391; United States / NIAID NIH HHS / AI / U01 AI035041; United States / NCI NIH HHS / CA / R01 CA67931; United States / NIAID NIH HHS / AI / U01-AI35041
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral
  • [Other-IDs] NLM/ PMC1594766
  •  go-up   go-down


68. Wilkins K, Turner R, Dolev JC, LeBoit PE, Berger TG, Maurer TA: Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol; 2006 Feb;54(2):189-206; quiz 207-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous malignancy and human immunodeficiency virus disease.
  • Certain skin cancers occur with increased frequency or altered course in patients infected with HIV.
  • Malignant melanoma and squamous cell carcinoma are examples of cutaneous malignancies that have a more aggressive course in patients with HIV.
  • The incidence of HIV-associated Kapsosi's sarcoma has markedly decreased since the advent of HIV antiretroviral therapy.
  • Cutaneous T-cell lymphoma (CTCL) is rare in this population.
  • Other types of cutaneous lymphoma and HIV-associated pseudo-CTCL are discussed.
  • LEARNING OBJECTIVE: At the completion of this learning activity, participants should be familiar with the unique epidemiology, clinical course, and management of cutaneous malignancy in patients infected with HIV.
  • [MeSH-major] HIV Infections / epidemiology. Skin Neoplasms / epidemiology
  • [MeSH-minor] Algorithms. Animals. Anti-Retroviral Agents / administration & dosage. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Herpesviridae Infections / epidemiology. Herpesvirus 8, Human / isolation & purification. Humans. Immunity, Cellular. Immunohistochemistry. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, T-Cell, Cutaneous / epidemiology. Lymphoma, T-Cell, Cutaneous / immunology. Lymphoma, T-Cell, Cutaneous / pathology. Melanoma / epidemiology. Melanoma / therapy. Papillomaviridae. Papillomavirus Infections / epidemiology. Risk Factors. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Seroepidemiologic Studies

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443048.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 274
  •  go-up   go-down


69. Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, Hughes MD, Aberg JA, Currier JS, Tashima K, Godfrey C, Greaves W, Flexner C, Skolnik PR, Wilkin TJ, Gulick RM, Kuritzkes DR: Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211. Clin Infect Dis; 2009 Mar 01;48(5):642-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
  • In a phase II trial of the investigational CCR5 antagonist vicriviroc (AIDS Clinical Trials Group protocol A5211), 4 lymphomas occurred in study patients who received vicriviroc.
  • Because of the known association between unregulated Epstein-Barr virus (EBV) replication and lymphoma in immunocompromised patients, we evaluated whether vicriviroc exposure was associated with lymphoma EBV antigen positivity and/or had an effect on plasma levels of EBV DNA.
  • METHODS: Clinical findings for all 4 patients enrolled in the A5211 study who developed lymphoma (2 Hodgkin and 2 non-Hodgkin) were reviewed, and tumor specimens were assessed for evidence of ongoing EBV replication.
  • RESULTS: Plasma EBV DNA was not detected in the 2 patients with non-Hodgkin lymphoma; both patients with Hodgkin lymphoma who had samples tested had EBV DNA levels <3200 copies/mL.
  • One patient with Hodgkin lymphoma had a lymph node core biopsy specimen that was strongly positive for EBV; the other 3 lymphomas were histochemically EBV negative.
  • CONCLUSIONS: CCR5 antagonism by vicriviroc treatment in treatment-experienced patients was not associated with reactivation of EBV infection.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Anti-HIV Agents / adverse effects. Epstein-Barr Virus Infections / diagnosis. Herpesvirus 4, Human / isolation & purification. Lymphoma / diagnosis. Piperazines / adverse effects. Pyrimidines / adverse effects. Viral Load

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Infect Dis. 2002 Aug 1;186(3):405-9 [12134237.001]
  • [Cites] J Med Virol. 2002 Jul;67(3):320-6 [12116021.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):717-45 [12852653.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):843-58 [12852658.001]
  • [Cites] Clin Infect Dis. 2003 Nov 1;37(9):1244-9 [14557970.001]
  • [Cites] N Engl J Med. 1988 Jan 14;318(2):76-81 [3336397.001]
  • [Cites] Ann Oncol. 1992 Sep;3 Suppl 4:117-28 [1450072.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):225-32 [8426198.001]
  • [Cites] Am J Epidemiol. 1994 Feb 15;139(4):362-8 [8109570.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):312-25 [8113838.001]
  • [Cites] Curr Opin Oncol. 1994 Sep;6(5):492-6 [7827152.001]
  • [Cites] J Immunol. 1998 Apr 15;160(8):4018-25 [9558111.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):442-8 [10404101.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] J Immunol. 1999 Nov 1;163(9):4642-6 [10528159.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):229-41; 260-1, 264 [16020424.001]
  • [Cites] J Exp Med. 2005 Oct 17;202(8):1087-98 [16230476.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):35-40 [16418398.001]
  • [Cites] J Gen Virol. 2006 Mar;87(Pt 3):489-99 [16476970.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96 [17005807.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] J Infect Dis. 2007 Jul 15;196(2):304-12 [17570119.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:204-9 [18024631.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] J Infect Dis. 2008 Jan 15;197(2):262-5 [18179388.001]
  • [Cites] J Infect Dis. 2008 Jan 15;197(2):266-9 [18179389.001]
  • [Cites] J Infect Dis. 2008 Mar 1;197(5):721-7 [18266604.001]
  • [Cites] J Infect Dis. 2008 Oct 15;198(8):1113-22 [18783318.001]
  • [Cites] N Engl J Med. 2008 Oct 2;359(14):1429-41 [18832244.001]
  • [Cites] N Engl J Med. 2008 Oct 2;359(14):1442-55 [18832245.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):712-5 [10655372.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):239-46 [11091207.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1165-71 [11222357.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1211-6 [11283029.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2339-44 [11588028.001]
  • [Cites] J Med Virol. 2001 Nov;65(3):543-52 [11596092.001]
  • [Cites] Blood. 2001 Dec 1;98(12):3406-12 [11719381.001]
  • [Cites] AIDS. 2002 Jan 4;16(1):63-73 [11741164.001]
  • [Cites] AIDS. 2002 May 3;16(7):993-1001 [11953465.001]
  • [Cites] J Neurovirol. 2002 Oct;8(5):432-8 [12402169.001]
  • (PMID = 19191652.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00082498
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI007387; United States / NIAID NIH HHS / AI / UM1 AI069472; United States / NCRR NIH HHS / RR / M01 RR000096; United States / NIAID NIH HHS / AI / AI069419; United States / NCRR NIH HHS / RR / UL1 RR024996; United States / NCRR NIH HHS / RR / K24 RR016482; United States / NCRR NIH HHS / RR / M01 RR000096-478528; United States / NIAID NIH HHS / AI / K23 AI055038; United States / NIAID NIH HHS / AI / U01 AI069532; United States / NIAID NIH HHS / AI / K24 AI051966; United States / NCRR NIH HHS / RR / M01 RR002635; United States / NIAID NIH HHS / AI / UM1 AI068634; United States / NIAID NIH HHS / AI / U01 AI069532-03; United States / NIAID NIH HHS / AI / AI068636; United States / NCRR NIH HHS / RR / RR02635; United States / NIAID NIH HHS / AI / U01 AI068636; United States / NIAID NIH HHS / AI / AI060354; United States / NIAID NIH HHS / AI / UM1 AI069419; United States / NIAID NIH HHS / AI / AI068634; United States / NIAID NIH HHS / AI / P30 AI060354; United States / NIAID NIH HHS / AI / AI055038; United States / NIAID NIH HHS / AI / U01 AI069419; United States / NCRR NIH HHS / RR / RR024996; United States / NCRR NIH HHS / RR / RR016482; United States / NIAID NIH HHS / AI / U01 AI069472; United States / NIAID NIH HHS / AI / U01 AI068634; United States / NIAID NIH HHS / AI / UM1 AI068636; United States / NCRR NIH HHS / RR / UL1 RR024979
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / DNA, Viral; 0 / Piperazines; 0 / Pyrimidines; TL515DW4QS / vicriviroc
  • [Other-IDs] NLM/ NIHMS144280; NLM/ PMC2756462
  •  go-up   go-down


70. Järviluoma A, Child ES, Sarek G, Sirimongkolkasem P, Peters G, Ojala PM, Mann DJ: Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol; 2006 Mar;26(6):2430-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • K cyclin encoded by Kaposi's sarcoma-associated herpesvirus confers resistance to the cyclin-dependent kinase (cdk) inhibitors p16Ink4A, p21Cip1, and p27Kip1 on the associated cdk6.
  • Here, we show that p21Cip1 is associated with K cyclin both in overexpression models and in primary effusion lymphoma cells and is a substrate of the K cyclin/cdk6 complex, resulting in phosphorylation of p21Cip1 on serine 130.
  • Moreover, we show that under physiological conditions of cell cycle arrest due to elevated levels of p21Cip1 resulting from oxidative stress, K cyclin expression enabled S-phase entry and was associated with p21Cip1 phosphorylation and partial restoration of cdk2 kinase activity.

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):33161-5 [10551888.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):656-66 [15870436.001]
  • [Cites] Curr Opin Genet Dev. 2000 Feb;10(1):70-4 [10679390.001]
  • [Cites] Virology. 2000 Jul 5;272(2):257-66 [10873769.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31145-54 [10878006.001]
  • [Cites] Biochim Biophys Acta. 2001 Mar 21;1471(3):M123-33 [11250068.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] J Pathol. 2001 May;194(1):35-42 [11329139.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3311-22 [11423981.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(16):5644-57 [11463845.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13761-70 [11827966.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29792-802 [12058028.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3840-4 [12839982.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25752-7 [12730199.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):138-40 [14712075.001]
  • [Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13496-505 [14726525.001]
  • [Cites] Anal Biochem. 1989 Feb 15;177(1):138-43 [2472754.001]
  • [Cites] Anal Biochem. 1991 Feb 1;192(2):262-7 [1852137.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2713-21 [8139570.001]
  • [Cites] Cell. 1994 Jul 15;78(1):59-66 [8033212.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):503-11 [7859739.001]
  • [Cites] J Biol Chem. 1995 Aug 4;270(31):18195-7 [7629134.001]
  • [Cites] Curr Biol. 1996 Apr 1;6(4):474-83 [8723352.001]
  • [Cites] Nature. 1996 Jul 25;382(6589):325-31 [8684460.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Cell Growth Differ. 1996 Feb;7(2):135-46 [8822197.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] Genes Dev. 1997 Apr 1;11(7):847-62 [9106657.001]
  • [Cites] J Virol. 1997 Jun;71(6):4193-8 [9151805.001]
  • [Cites] Nature. 1997 Nov 13;390(6656):184-7 [9367157.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):644-53 [9927424.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):654-63 [9927425.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):223-8 [10329038.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5310-20 [10508164.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3349-54 [15271792.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Science. 1993 Dec 24;262(5142):2050-4 [8266103.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] Mol Carcinog. 2000 Feb;27(2):141-8 [10657906.001]
  • (PMID = 16508017.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/C508134/1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / K cyclin protein, Herpesvirus 8, Human; 0 / Recombinant Proteins; 0 / Viral Proteins; 452VLY9402 / Serine; EC 2.7.11.22 / Cdk2 protein, mouse; EC 2.7.11.22 / Cdk6 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  • [Other-IDs] NLM/ PMC1430279
  •  go-up   go-down


71. Ho SF, Fink C, Murray PI: Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma. Ocul Immunol Inflamm; 2005 Dec;13(6):471-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr Virus DNA quantification: an adjunctive diagnostic marker for AIDS-associated lymphoma.
  • We report an HIV-positive patient who developed a unilateral retinitis and subsequent intracranial lesions.
  • The finding of Epstein Barr virus (EBV) DNA at a > 1-log greater concentration in the vitreous compared to blood raised the possibility of a primary CNS non-Hodgkin's lymphoma, which was subsequently confirmed on brain biopsy.
  • [MeSH-major] DNA, Viral / genetics. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321894.001).
  • [ISSN] 0927-3948
  • [Journal-full-title] Ocular immunology and inflammation
  • [ISO-abbreviation] Ocul. Immunol. Inflamm.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


72. Fellner MD, Durand K, Correa RM, Redini L, Yampolsky C, Colobraro A, Sevlever G, Teyssié AR, Benetucci J, Picconi MA: Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis; 2007 Mar;11(2):172-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma.
  • OBJECTIVE: To analyze Epstein-Barr virus (EBV) load at different HIV infection stages and its relation with brain lymphoma.
  • DESIGN: A cross-sectional study was conducted on 172 HIV-infected individuals: 62 asymptomatic HIV carriers (group A), 30 HIV progressors (group B), 73 AIDS patients (group C), seven AIDS patients with brain lymphoma (group C-BL); and 26 blood donors (group BD) as healthy carriers.
  • RESULTS: PBMC-EBV levels in HIV-infected patients were higher than in the blood donors (p<0.05).
  • Similar PBMC-EBV loads were seen in HIV-infected patients with CD4+ T cell counts higher than 50/mm(3) (p>0.05), while significantly lower levels were found in cases with less than 50 cells/mm(3) (p<0.05).
  • In all HIV-infected patients, plasma-EBV load was lower than, or similar to, PBMC-EBV load, unlike 2/7 HIV-positive brain lymphoma patients.
  • CONCLUSIONS: During HIV infection PBMC-EBV load rises in comparison to healthy carriers, but decreases when immunosuppression progresses and CD4+ T cell count becomes <50/mm(3).
  • Circulating EBV is mainly cell-associated in the HIV-infected population.
  • Neither PBMC-EBV nor plasma-EBV loads would be useful to diagnose brain lymphoma in AIDS patients.
  • [MeSH-major] Brain Neoplasms / virology. HIV Infections / virology. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16931088.001).
  • [ISSN] 1201-9712
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


73. Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E, Banham AH, Noy A, Kaplan LD, Sparano JA, Bhatia K, Cesarman E: Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol; 2009 Oct 20;27(30):5039-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034.
  • PURPOSE: Diffuse large B-cell lymphoma (DLBCL) represents a clinically heterogeneous disease.
  • We sought to determine whether immunohistochemical analyses of biopsies from patients with DLBCL having HIV infection are similarly relevant for prognosis.
  • PATIENTS AND METHODS: We examined 81 DLBCLs from patients with AIDS in AMC010 (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] v CHOP-rituximab) and AMC034 (etoposide, doxorubicin, vincristine, prednisone, and dose-adjusted cyclophosphamide plus rituximab concurrent v sequential) clinical trials and compared the immunophenotype with survival data, Epstein-Barr virus (EBV) positivity, and CD4 counts.
  • Expression of FOXP1, Blimp-1/PRDM1, or BCL-2 was not correlated with the outcome in patients with AIDS-related DLBCL.
  • CONCLUSION: These data indicate that with current treatment strategies for lymphoma and control of HIV infection, commonly used immunohistochemical markers may not be clinically relevant in HIV-infected patients with DLBCL.
  • The only predictive immunohistochemical marker was found to be Ki-67, where a higher proliferation index was associated with better survival, suggesting a better response to therapy in patients whose tumors had higher proliferation rates.
  • [MeSH-major] Immunophenotyping. Ki-67 Antigen. Lymphoma, AIDS-Related / immunology. Lymphoma, Large B-Cell, Diffuse / immunology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4):441-51, 456, 459 [12017534.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):22-9 [12517536.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2363-7 [12424193.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):464-70 [15087665.001]
  • [Cites] Ann Hematol. 2004 Jul;83(7):414-9 [15085385.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2933-5 [15238418.001]
  • [Cites] Blood. 1988 Apr;71(4):1157-60 [3281723.001]
  • [Cites] Lancet. 1991 Feb 9;337(8737):320-2 [1671232.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 1:113-6 [8172807.001]
  • [Cites] Blood. 1997 Jan 15;89(2):601-9 [9002964.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1931-9 [9586912.001]
  • [Cites] Leuk Lymphoma. 1998 Aug;30(5-6):515-24 [9711914.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1065-72 [15709173.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1762-9 [15905193.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1538-43 [15914552.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9067-72 [16172462.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):438-46 [16444194.001]
  • [Cites] Haematologica. 2006 Apr;91(4):467-74 [16585013.001]
  • [Cites] Microbes Infect. 2006 Apr;8(5):1301-7 [16697236.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 May;6(6):455-7 [16796775.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4135-42 [16943530.001]
  • [Cites] Ann Oncol. 2007 May;18(5):931-9 [17395602.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Histopathology. 2007 Jul;51(1):70-9 [17593082.001]
  • [Cites] Curr Opin Oncol. 2007 Sep;19(5):458-63 [17762571.001]
  • [Cites] Eur J Haematol. 2007 Dec;79(6):501-7 [17986209.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2816-24 [18077790.001]
  • [Cites] Annu Rev Immunol. 2008;26:133-69 [18370921.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2717-24 [18378569.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 [18765795.001]
  • [Cites] Nat Rev Immunol. 2007 Dec;7(12):923-7 [17965637.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):920-32 [12461565.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [CommentIn] J Clin Oncol. 2010 Jun 1;28(16):e260; author reply e261-2 [20421532.001]
  • (PMID = 19752343.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / CA-121947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC2799056
  •  go-up   go-down


74. Ruiz G, Peña P, de Ory F, Echevarría JE: Comparison of commercial real-time PCR assays for quantification of Epstein-Barr virus DNA. J Clin Microbiol; 2005 May;43(5):2053-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical research suggests a role for viral load measurement in predicting and monitoring Epstein-Barr virus (EBV)-associated diseases.
  • A total of 87 samples were analyzed: 67 samples were obtained from transplant recipients and patients with EBV-associated diseases, 8 samples were obtained from the Quality Control for Molecular Diagnostics 2002 EBV Proficiency Program, and 12 negative qualitative nested PCR samples were used as negative controls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transplantation. 2001 Sep 27;72(6):1012-9 [11579293.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):55-61 [11333300.001]
  • [Cites] Mol Diagn. 2001 Dec;6(4):279-89 [11774193.001]
  • [Cites] J Med Virol. 2002 Mar;66(3):360-9 [11793388.001]
  • [Cites] Clin Transplant. 2002 Apr;16(2):107-12 [11966780.001]
  • [Cites] Exp Hematol. 2002 Jun;30(6):503-12 [12063017.001]
  • [Cites] Ann Neurol. 2002 Nov;52(5):543-8 [12402250.001]
  • [Cites] J Neurovirol. 2002 Oct;8(5):432-8 [12402169.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):3986-92 [12409363.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):489-96 [12450734.001]
  • [Cites] Lancet Infect Dis. 2003 Mar;3(3):131-40 [12614729.001]
  • [Cites] J Virol Methods. 2003 May;109(2):227-33 [12711067.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5108-21 [12910248.001]
  • [Cites] Pediatr Infect Dis J. 2003 Aug;22(8):736-9 [12913777.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1215-21 [12916875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Apr;80(7):1987-91 [6300885.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] AIDS. 1996 Aug;10(9):935-40 [8853725.001]
  • [Cites] J Clin Microbiol. 1999 Jan;37(1):132-6 [9854077.001]
  • [Cites] J Virol Methods. 1999 Apr;79(1):9-19 [10328531.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1165-71 [11222357.001]
  • [Cites] J Med Virol. 2001 Nov;65(3):543-52 [11596092.001]
  • (PMID = 15872221.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC1153768
  •  go-up   go-down


75. Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B: The changing face of HIV/AIDS in treated patients. Curr HIV Res; 2009 Jul;7(4):365-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The changing face of HIV/AIDS in treated patients.
  • The spectrum of complications emerging in successfully treated HIV-infected patients has dramatically changed since the advent of HAART.
  • Typical AIDS-defining illnesses hav